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Resumo 
 
A doença de Farber é uma esfingolipidose fatal, causada pela deficiente atividade 
da ceramidase ácida. 
Esta hidrolase é responsável pela degradação da ceramida em esfingosina e ácidos 
gordos livres no interior dos lisossomas. Embora os avanços científicos sejam 
consideráveis, no conhecimento das bases genética e bioquímica da deficiência em 
ceramidase ácida, pouco é o que se sabe acerca da patogenesis molecular da doença.  
Um evento patogénico comum em diversas esfingolipidoses pode residir no 
bloqueio de transporte intracelular do lisossoma ou para o lisossoma, em pontos 
celulares relacionados e com consequente atraso endossomal/lisossomal. 
O presente estudo investiga alterações lipídicas secundarias em fibroblastos de 
doentes de Farber bem como a existência e localização de domínios ordenados 
compostos por C16- ou C18-ceramida, e colesterol nas diferentes membranas biológicas 
em diferentes linhas celulares, dando enfâse à doença de Farber.  
A marcação intensa pela coloração de Filipina, é indicativa de altos níveis 
intracelulares de colesterol não esterificado, e foi observado depois da sobrecarga com 
LDL, em doentes com deficiência em ceramidase ácida. 
Foi obtida uma observação semelhante com o gangliosido GM2. Através da 
microscopia de fluorescência, o BODIPY-LacCer é endocitado a partir da membrana 
plasmática até aos endosomas/lysosomas, em contraste com o controlo negativo onde o 
análogo lipídico foi transportado até ao complexo de Golgi. 
Relativamente ao BODIPY-C5-Cer, um aumentos dos níveis no complexo de Golgi 
foi observado em doentes de Farber. Quando os fibroblastos de doentes de Farber foram 
marcados  com o anticorpo anti C16-Cereramida/Colesterol, foi observado um aumento 
dos níveis dos domínios Ceramida/Colesterol  em doentes do tipo 4 e 7, as formas mais 
severas da doença. Depois da sobrexpressão da ceramidase ácida verificou-se a 
correção do tráfego observado em fibroblastos de doentes de Farber, deficientes em 
ceramidase ácida, e observou-se que ao reduzir os níveis de ceramida ou colesterol os 
domínios ceramida/colesterol diminuíram.  
Estes dados fornecem uma importante evidência do nível de ceramida lisossomal 
para a homeostasia lipídica e que, quando alterados, pode levar a um nível de 
desequilíbrio de esfingolípidos e colesterol e, subsequentemente, a alterações nas vias 
de sinalização celular específicos, com impacto no tráfico intracelular de lípidos e 
domínios lipídicos. 
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Palavras-Chave 
 
Doença de Farber, Ceramida, domínios lipídicos, doença de armazenamento. 
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Abstract 
 
Farber disease (FD) is a fatal sphingolipidosis caused by the deficient activity of acid 
ceramidase (ACDase). This hydrolase is responsible for the degradation of ceramide 
(Cer) into sphingosine and free fatty acid in lysosomes. Although some advances have 
been made in the knowledge of the genetic and biochemical bases of ACDase-deficiency, 
little is known about the disease molecular pathogenesis. One pathogenic event common 
to several sphingolipidoses could reside in blocking of intracellular transport to or from 
lysosomes at several related cellular points with subsequent endosomal/lysosomal jam. 
In this study we investigated secondary lipid accumulations in FD fibroblasts 
patients as well as the existence and location of ordered domains composed of C16- or 
C18-ceramide and cholesterol (Chol) in different biological membranes in different types 
of cells, giving emphasis to FD. 
Increased filipin staining, indicative of high levels of intracellular unesterified Chol, 
was observed in ACDase-deficient cells after LDL overload. A similar observation was 
made for the ganglioside GM2. By fluorescence microscopy BODIPY-LacCer was found 
to be endocytosed from the plasma membrane (PM) to endosomes/lysosomes, in contrast 
to normal control cells where the lipid analog was transported to the Golgi complex. For 
BODIPY-C5-Cer, an increased level at the Golgi complex was seen in FD cells. Labeling 
of fibroblasts from patients with FD with an anti-C16-Cer/Chol antibody revealed an 
elevation in the Cer/Chol domains in type 4 and 7 FD, the most severe form of the 
disease. Overexpression of ACDase corrected lipid traffic imbalances observed in 
ACDase-deficient fibroblasts, and reducing Cer or Chol levels could modulate the 
Cer/Chol domains elevation. 
These data provide evidence for the importance of a steady-state level of lysosomal 
Cer for lipid homeostasis that, when disrupted, may lead to an unbalanced level of 
sphingolipids and Chol and subsequently, to alterations in specific cell signaling pathways 
with impact in intracellular lipid trafficking and lipid domains.  
 
Keywords 
Farber disease, ceramide, lipid domains, storage disease. 
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Introduction 
 
1. Lysosomes 
 
Lysosomes were first discovered and characterized by Christian de Duve and 
coworkers in the late 1950s and early 1960s (de Duve, 1959), as a result of studying the 
intracellular distribution of enzymes using centrifugal fractionation, cytological studies and 
biochemical analyses (de Duve et al., 1955). Due to his discovery de Duve was awarded 
the Nobel Prize in 1974 (de Duve, 1959; Duve, 1975). De Duve defined lysosome as a 
group of cytoplasmic particles surrounded by a lipoprotein membrane that contain a 
variety of acid hydrolases (de Duve and Wattiaux, 1966). Lysosomes are present in 
almost all cell types and their number depending on cell type and function (Wevers and 
Gieselmann, 2005). 
 
Lysosomes are ubiquitous acidic vacuoles containing more than 50 different soluble 
lysosomal hydrolases including, glycosidases, proteases, lipases, nucleases, 
phospholipases, phosphatases, and sulfatases, that have acid pH optima and possess a 
major role in degradation of macromolecules from the secretory, endocytic, autophagic 
and phagocytic membrane-trafficking pathways (Wevers and Gieselmann, 2005; Luzio et 
al., 2007).  
 
In addition to these acid hydrolases there are over 120 lysosomal membrane 
proteins. Lysosomal associated membrane protein type 1 (LAMP-1), lysosomal 
associated membrane protein type 2 (LAMP-2) and lysosomal integral membrane protein 
type 2 (LIMP-2) are the most abundant, and some of these membrane proteins are 
responsible for the transport of the other soluble enzymes and non-enzymes proteins in 
mannose 6-phosphate-independent transport (Braulke and Bonifacino, 2009).  
 
During the past decade much has been discovered about many aspects of 
lysosome biogenesis. The selective phosphorylation of mannose residues on lysosomal 
enzymes, in conjunction with specific receptors for the mannose 6-phosphate (M6P) 
recognition marker, is found to be largely responsible for the targeting or "sorting" of newly 
synthesized lysosomal enzymes (Kornfeld and Mellman, 1989). 
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1.1. Ultra-Structure  
Lysosomes were initially discovered by the biochemical fractionation of cell extracts 
and only later they were seen clearly by electron microscopy (Alberts et al., 2002). By 
electron microscopy studies, De Duve and co-workers demonstrated that lysosomes 
constitute up to 5% of the intracellular, are of heterogeneous size and morphology, and 
can often contain electron-dense deposits (Luzio et al., 2007). Lysosomes can be 
described as “dense bodies”, that are delimited by a single membrane and having an 
electron-dense content (Holtzman, 1989).  They assume so many different forms 
additional to the dense bodies, reason why they cannot be recognized by the canonical 
morphological criteria of size, shape and internal structure, since these organelles vary 
significantly (Duve, 1983). They display considerable structural heterogeneity and appear 
in all shapes, sizes and densities (Wevers and Gieselmann, 2005). Lysosomes (Figure 1) 
are characteristically observed by electron microscopy as organelles of ~0.5 µm diameter 
and often have electron-dense cores. One marker used to identify this organelle was acid 
phosphatase (Holtzman, 1989). This enzyme can be identified histochemically and, thus, 
used in electron microscopy techniques (Weissmann, 1964). Morphologically, 
conventional lysosome is multi-vesicular in structure, as it contains internal vesicles that 
have budded off from the limiting membrane in a similar manner to a late endosome or 
multi-vesicular body (MVB) (Blott and Griffiths, 2002).  
 
 
Figure  1- A- Electron micrograph of lysosomes. G-Lysosomes; N-Nucleus (Weissman, 1964). B and C correspond to a 
multilamellar structure of lysosomes (Taken from Ohshima et al., 1997).  
 
A 
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1.2. Biogenesis 
 
Lysosomal enzymes, along with secretory proteins and PM proteins, are 
synthesized on membrane-bound polyribosomes on the rough endoplasmic reticulum 
(RER) (Wevers and Gieselmann, 2005; Ni et al., 2006). After their synthesis, lysosomal 
proteins are sorted initially via signal peptides into the lumen of the endoplasmic reticulum 
(ER) (Wevers and Gieselmann, 2005). In this organelle lysosomal enzymes undergo 
glycosylation. This step involves the transfer of large oligosaccharide residues of the 
nascent protein (Wevers and Gieselmann, 2005). Then the signal peptide is cleaved, the 
protein folds, and the processing of the asparagine-linked oligosaccharide begins (Wevers 
and Gieselmann, 2005). Upon exit from the ER the N-glycosylated lysosomal pro-
hydrolases travel via vesicular transport to the Golgi apparatus to acquire the M6P group 
(Castino and Isidoro, 2008). So these pro-hydrolases carry a unique marker in the form of 
M6P groups, which are added exclusively to the N-linked oligosaccharides of these 
soluble lysosomal enzymes as they pass through the lumen of the cis Golgi network 
(Alberts et al., 2002). In the cis compartment of the Golgi complex, oligosaccharide side 
chains of lysosomal enzymes are phosphorylated and thus acquire M6P moieties (Wevers 
and Gieselmann, 2005). These reactions occur in distinct compartments along the 
secretory pathway (Castino and Isidoro, 2008). 
 
The synthesis of the M6P residues is initiated by a phosphotransferase, witch 
specifically recognizes lysosomal enzymes (Wevers and Gieselmann, 2005). This 
recognition is mediated by spatial signal depending on the three-dimensional structure of 
the enzymes. Only surface-located lysine residues seem to be an essential common 
component of this topogenic signal (Alberts et al., 2002). The M6P groups are recognized 
by transmembrane mannose 6-phosphate receptor (MPRs) proteins, which are present in 
the trans Golgi network (TGN). The receptor proteins bind to lysosomal hydrolases on the 
luminal side of the membrane and to adaptins in assembling clathrin coats on the 
cytosolic side (Figure 2) (Alberts et al., 2002). In this way, they help package the 
hydrolases into clathrin-coated vesicles that bud from the trans Golgi network. The 
vesicles subsequently deliver their contents to a late endosome (Alberts et al., 2002). The 
two-MPRs were identified because of their ability to bind M6P-containing soluble acid 
hydrolases in the Golgi and transport them to the endosomal-lysosomal system (Wevers 
and Gieselmann, 2005).  
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Figure  2 - Model for lysosomal enzyme targeting to lysosomes.  
Lysosomal hydrolases and secretory proteins are synthesized in the RER and transported to the Golgi where the lysosomal 
enzymes acquire phosphomanosytol residues. Lysosomal biogenesis involves biosynthetic and endocytic pathways (green 
arrows). The soluble lysosomal proteins leave the ER, where they are synthesized, by vesicular transport passing through 
the ER-Golgi intermediate compartment. From the TGN, they can follow the constitutive secretory pathway (blue arrows) to 
the PM and subsequently reach lysosomes by endocytosis. Lysosomal proteins can go straight to the intracellular pathway 
(red arrows) to the endo-lysosomal system. Clathrin-dependent transport of lysosomal hydrolases is implicated in MPRs. 
Grey arrows represent endo-lysosomal pathways at distinct stages of maturation. The black arrows represent multiple 
retrograde pathways from endosomes (Taken from Saftig and Klumperman, 2009). 
 
The bound hydrolases are first delivered to endosomes, where they dissociate from 
the receptors as a result of the acidic luminal pH. Lysosomes can be distinguished from 
endosomes by the absence of MPRs. This allows the receptors to recycle back to the 
Golgi apparatus and the hydrolases continue the transport to the lysosomes (Luzio et al., 
2000). Unlike soluble hydrolases, the delivery of newly synthesized lysosomal membrane 
proteins from the Golgi complex does not require their binding to MPRs, and occurs either 
by an indirect route via the PM or by a direct intracellular route (Luzio et al., 2007).  
 
In mammalian cells, the majority of soluble acid hydrolases are modified with M6P 
residues, allowing their recognition by MPRs in the Golgi complex and ensuing transport 
to the endosomal/lysosomal system. However, in addition to this M6P transport route, 
other soluble enzymes and non-enzymatic proteins are transported to lysosomes in an 
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M6P-independent manner mediated by alternative receptors such as the lysosomal 
integral membrane protein sortilin or LIMP-2 (Lefrancois et al., 2003; Mari et al., 2008). 
Sortilin is a protein with 100 KDa and belongs to a growing family of multiligand type-1 
(Lefrancois et al., 2003; Westergaard et al., 2004). This transporter has been reported to 
mediate lysosomal trafficking of prosaposin and acid sphingomyelinase (ASMase) 
(Braulke and Bonifacino, 2009). Recently, the LIMP-2, a heavily N-glycosylated type III 
transmembrane protein, has been identified as a specific receptor for lysosomal targeting 
of β-glucocerebrosidase in an M6P-independent manner (Braulke and Bonifacino, 2009). 
The complex interaction of both luminal and cytosolic signals with recognition proteins 
guarantees the specific and directed transport of proteins to lysosomes (Braulke and 
Bonifacino, 2009). 
 
 
1.3. Function 
 
Lysosomes are membrane-bound organelles that are present in virtually all 
eukaryotic cells. They represent the final destination for a significant fraction of all 
intracellular traffic, and is one of the most important intracellular mechanisms for the 
turnover of endogenous and exogenous macromolecules (Kornfeld and Mellman, 1989). 
The catabolism occurs in the lumen of lysosomes by a combination of predominantly 
hydrolytic enzymes with acidic pH-optima ranging from 4.6–5.0, provided by proton-
pumping vacuolar adenosine triphosphatases (ATPases) (Luzio et al., 2007). The 
lysosomal membrane separates the hydrolytic enzymes from the cytoplasm to protect 
against attack by the cell´s own digestive system (Alberts et al., 2002).  
 
Lysosomes are acidic pH hydrolase-rich vacuoles and they are responsible for 
degradation of a variety of substances from the extracellular space by endocytosis, 
delivered by fusion with phagosomes or autophagosomes, or derived from the 
biosynthetic pathway, such as proteins, glycosaminoglycans, nucleic acids, 
oligosaccharides, and complex lipids, into their building blocks that are available for 
metabolic re-use (Luzio et al., 2000; 2007).  
 
These compartments eventually fuse with primary lysosomes to form various types 
of secondary lysosomes, and can include autophagic vacuoles, multilamellar bodies 
(MLB), MVB, and dense bodies (Nixon and Cataldo, 1993) (Figure 3). These secondary 
lysosomes can reflect the nature of the internalized material and may indicate the states in 
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the digestion process and can be identify by electron microscopy (de Duve and Wattiaux, 
1966). Lysosomes are distinguished from endosomes by the absence of the two MPRs 
and recycling cell surface receptors (Luzio et al., 2000). 
 
 
Figure  3- Scheme of the lysosomal system representing endocytic and autophagic pathways. (B-E) ultrastructure of the 
lysosome 
A -. Pre-autophagic structure (PAS) sequesters large areas of cytoplasm within a double membrane-limited autophagosome 
(AP). This organelle fuses with a lysosome to form an autophagolysosome (AL) or with a late endosome/multivesicular body 
(LE/MVB) to form an amphisome.  (B) Internalized materials entering the endocytic pathway are directed to early (sorting) 
endosomes (EE), which mature to LE/MVB. (C) An autophagosome, which is hydrolase- negative, contains recognizable 
but partially digested organelle compartments. (D) Another type of immature autophagic vacuoles (AV) is double-membrane 
limited and contains heterogeneous intraluminal materials, including other organelles. (E) Following further substrate 
digestion, the content of an autolysosomes is amorphous and less dense. Complete digestion of substrates within 
autolysosomes ultimately yields lysosomes, which are smaller, less dense vesicles containing mainly lysosomal hydrolases 
(E). Bar, 500 nm (Taken from Nixon, 2007). 
 
The mechanism of transport of the endocytosed material from endosomes to 
lysosomes remains controversial, and several theories were proposed (Luzio et al., 2007). 
Three alternative hypotheses are available. These include: (i) Maturation of the endosome 
into a lysosome, that involves formation of EE by coalescence of vesicles from the PM; (ii) 
Vesicular transport with vesicles carrying cargo from endosomes to lysosomes, 
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postulating that EE, LE and lysosomes are stable compartments; (iii) Kiss-and-run, a 
continuous repeated cycles of fusion and fission, during which material is transferred 
between the organelles and each contact is followed by a dissociation or ‘run’ (Storrie and 
Desjardins, 1996; Luzio et al., 2000; 2007). A recently proposed variation of “kiss-and-
run”, direct fusion, in which lysosomes reform from hybrid organelles as a result of fission 
events (de Duve et al., 1955; Luzio et al., 2000; 2007). These models are not mutually 
exclusive and it is possible that cells employ more than one of these processes in 
lysosomal biogenesis (de Duve, 1959; Duve, 1975; Luzio et al., 2000; 2007). 
 
Lysosomes used to be considered just as a degradation organelle (Figure 4). 
However, recent studies of lysosomes and their proteins in association with endosomal, 
autophagosomal, and related vesicular systems, have re-conceptualized lysosomes as 
vital recycling centers, influencing signal transduction and regulation of gene expression. 
The Transcription Factor EB (TFEB) positively regulates these key processes by 
regulating the Coordinated Lysosomal Expression and Regulation (CLEAR) network. 
Genes that belong to this pathway are involved in lysosomal biogenesis, exocytosis and 
autophagy (Settembre et al., 2013). 
 
Lysosomes play critical roles in other cellular processes. They also fuse with the PM 
during cell injury, as well as having more specialized secretory functions in some cell 
types (de Duve and Wattiaux, 1966; Luzio et al., 2007). Not so far was fond another 
important function for lysosome, related to sensing and signaling pathways. This complex 
mechanism can sense nutrient availability and activate a lysosome-to-nucleus signaling 
pathway that is involved in cell metabolism and growth (Wevers and Gieselmann, 2005; 
Settembre et al., 2013). In addition, recent studies suggest new lysosomal function, they 
can be involved in membrane repair (Wevers and Gieselmann, 2005; Luzio et al., 2007).  
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Figure  4- Main functions of the lysosome.  
Lysosomes can be involved in many functions such as, degradation and recycling of intracellular substrates; specialized 
secretion; PM repair; degradation and recycling of extracellular substrates; nutrient sensing and control of energy 
metabolism; feedback control of lysosomal biogenesis (Taken from Settembre et al., 2013) 
 
2. Sphingolipids  
 
The prefix sphingo derives from the Greek myth of the sphinx and signifies the 
magnitude of the riddle associated with the function of these molecules (Kornfeld and 
Mellman, 1989; Nyberg et al., 1998). Sphingolipids (SLs) represent a major class of lipids 
that are ubiquitous constituents of membranes in all animals. However they can also be 
found in plants, fungi, as well as some prokaryotic organisms and viruses (Alfred H Merrill 
and Hannun, 2000; Alberts et al., 2002; Bartke and Hannun, 2009).  
 
More than 300 different types of complex SLs have been reported, in various 
mammalian cell types (Hannun and Bell, 1989; Alfred H Merrill and Hannun, 2000; Luzio 
et al., 2007). Many authors contributed to their discovery, but one can be considered the 
father of sphingolipid (SL) research. In 1884 Johann L. W. Tudichum published their 
findings in a book entitled A Treatise on the Chemical Constitution of the Brain (Holtzman, 
1989; Yamakawa, 1996; Alfred H Merrill and Hannun, 2000; Anon, 2000; Merrill and 
Sandhoff, 2002). He was a German clinician with training in chemistry and isolated an 
organic base that he called sphingosine (Duve, 1983; Yamakawa, 1996). He also isolated 
and named several lipids such as cerebroside, Cer, sphingomyelin (SM), and cephalin 
from human brain (Thudichum, 1884; Wevers and Gieselmann, 2005).  
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The selective degradation of intra-lumenal mem-
branes and lipids within lysosomes occurs in specialized 
intra-lysosomal vesicles. These vesicles contain a com-
plex machinery composed of proteins that are involved in 
lipid degradation, such as water-soluble acid hydrolases 
and sphingolipid activator proteins (SAPs)35–39. Studying 
glycosphingolipid catabolism in patients with defects in 
this process was instrumental for the understandin g of 
this complex pathway40–42.
Importantly, a number of non-lysosomal proteins 
modulate the functions of lysosome-resi ent proteins. 
Prominent examples of these are the two different types 
of MPRs, cation-indepe dent MPR (CI-MPR) and 
cation-dependent MPR (CD-MPR), which dynami-
cally shuttle between the trans-Golgi network (TGN) 
and late endosomes and are involved in the targeting of 
lysosomal enzymes to the lysosome32. Another example 
is sulphatase-modifying factor 1 (SUMF1), an endo-
plasmic reticulum (ER)-resident protein that is respon-
sible for a post-translational modification (PTM), the 
conversion of a highly conserved Cys in the active site 
to α-formylglycine, which is required for the activation 
of all sulphatases43,44.
Various methods have been u ed to purify lyso somes 
and analyse their proteome45–49. Some of these approaches 
are based on subcellular fractionations, whereas thers are 
based on specific features of soluble lysosomal proteins, 
such as the mannose-6-phosphate modification of their 
carbohydrate moieties49. In these efforts, it has been 
difficult to distinguish between lysosome-resident pro-
teins, which are constituents of the lyso somal machin-
ery, and proteins that are delivered to the lysosome for 
degradation. Therefore, we are still far from the iden-
tification and functional characterization of all lyso-
somal proteins. On the basis of current data, a little over 
100 bona fide lysosome-resident proteins have been 
identified; ~70 of these are lysosomal matrix proteins 
and ~50 are lysosomal membrane proteins48. However, 
these numbers are likely to increase in the near future.
Lysosome functions
Lysosomal functions can be schematically divided into 
three main types: degradation, secretion and signalling 
(FIG. 1).
Lysosome-mediated degradation. Similar to the trans-
port of urban waste to incinerators, the collection and 
transport of cellular waste to lysosomes requires com-
plex logistics. The cell has developed different routes for 
transporting extracellular and intracellular waste to the 
lysosome. Extracellular material reaches the lysosome 
mainly through endocytosis. The capture of extra-
cellular material and integral membrane proteins occurs 
through specific endocytic mechanisms according to the 
nature of the cargo. Prominent examples of endocytosis 
are phagocytosis, macropinocytosis, clathrin-mediated 
endocytosis, caveolin-mediated endocytosis and clathrin- 
and caveolin-independent endocytosis50. Signalling 
receptors may undergo endocytosis through clathrin-
mediated endocytosis51 or clathrin-independent mecha-
nisms52. After internalization, the receptors are routed to 
early endosomes53. From the endosomes, the receptors 
can either be recycled back to the plasma membrane to 
allow for repeated receptor activation or be sorted and 
targeted for lysosomal degradation, resulting in the 
termin ation of receptor signalling54–56.
A known hallmark of endosome-to-lysosome matu-
ration is the progressive decrease of the internal pH to 
~pH 5 in the mature lysosome57. This is crucial for the 
uptake of acid hydrolases by MPRs into the endosomal 
lumen and the recycling of receptors back to the Golgi 
network15. Th  generation and maintenance of the lyso-
somal pH gradient requires the activity of a proton-
pumping v-type ATPase, which uses the energy of ATP 
hydrolysis to pump protons into the lysosomal lumen58. 
Additional lysosomal membrane channels are thought to 
be involved in lysosomal acidification, such as the anion 
transporter chloride channel 7 (ClC7)59–62 and the catio n 
transporters mucolipin 1 (MCOLN1; also known as 
TRPML1) and two pore calcium chann el 1 (TPC1) 
and TCP2 (REF. 62), which mediate Ca2+ and Na+ release 
from the lysosome62–65, 106. However, the role of each of 
these channels and the precise mechanisms underlying 
the complex regulation of lysosomal acidification and 
ion balance are still controversial and require further 
investigation.
Intracellular materials reach the lysosome through the 
process of autophagy, a Ƞself-eatingȞ catabolic pathway 
that is used by cells to capture their own cytoplasmic 
components destined for degradation and recycling. 
Three types of autophagy have been identified: micro-
autophagy; chaperone-mediated autophagy (CMA); 
and macroautophagy. During microautophagy, cytosolic 
Figure 1 | Main functions of the lysosome and their relationship with key cellular 
processes. Lysosomes are involved in the degradation and recycling of intracellular 
material (via autophagy) and extracellular material (via endocytosis). In these processes, 
lysosomes fuse with autophagosomes and with late endosomes, respectively. 
6JG|TGUWNVKPIDTGCMFQYPRTQFWEVUCTGWUGFVQIGPGTCVGPGYEGNNWNCTEQORQPGPVUCPF
energy in response to the nutritional needs of the cell. Lysosomes also undergo Ca2+ 
regulated exocytosis to secrete their content into the extracellular space and to repair 
damaged plasma membranes. Upon plasma membran  injury, lysosomes rapidly migrate 
to the damaged site and fuse with the plasma membrane to allow efficient resealing. 
More recently, lysosomes have been identified as signalling organelles that can sense 
nutrient availability and activate a lysosome-to-nucleus signalling pathway that 
mediates the starvation response and regulates energy metabolism.
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2.1. Structure  
 
SLs are amphipathic molecules that have both hydrophobic and hydrophilic 
properties, consisting of a long chain base, usually sphinganine or sphingosine, attached 
to a fatty acid via an amide bond. The hydrophobic region consists of a sphingoid long 
chain base (normally sphingosine, sphinganine or phytosphingosine) to which a fatty acid 
is attached by an amide bond to carbon 2 (Holtzman, 1989; Merrill et al., 2001; Merrill and 
Sandhoff, 2002; Futerman and Hannun, 2004; Kacher and Futerman, 2006) (Figure 5). 
Sphingosine is the prevalent backbone of mammalian SLs and is sometimes used as a 
generic term for all sphingoid bases (Thudichum, 1884; Weissmann, 1964; Merrill et al., 
2001).  
 
Figure  5- Chemical structures of SLs 
SLs are amphipathic molecules having both hydrophobic and hydrophilic properties, consisting of a long chain base, usually 
sphinganine or sphingosine, attached to a fatty acid via an amide bond, and usually contain different head groups. Cer, the 
backbone of all SLs, is composed of a long chain base acylated with a fatty acid. A major constituent of cell membranes, 
SM, comprises a Cer unit and a phosphorylcholine or phosphoethanolamine polar headgroup. SLs can have a sugar head 
groups that can vary in complexity from a single glucose (glucosylceramide) or galactose (galactosylceramide), in the case 
of cerebrosides. To more complex structures, such as lactosylceramide with two sugars. Certain sub-clases are recognized 
by additional components, such as sulfatides, which contain sulfate, and gangliosides, which contain sialic acid residues 
(Taken from Guo et al., 2005). 
 
Sphingolipids are a big class of complex lipids whose core structure is long-chain
amino alcohol, commo ly trans-1,3-dihydroxy-2-amino-4- tadecene, sphingosine in
mammals (Olsen and Janzen, 2001; Vesper et al., 1999) (Fig. 2). However, the structure of
sphingosine molecules may vary in alkyl chain lengths (from 14 to 22 carbon atoms),
degree of saturation and position of the double bonds, presence of a hydroxyl group at
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Cer (N-acyl-sphingosine) is the backbone of all SLs, which are essential 
constituents of eukaryotic membranes. This simple SL is composed of a fatty acid 
attached to a long chain base via an amide bond. The composition of the fatty acids in Cer 
vary in length, typically 14 to 24 carbon atoms, and degree of saturation, normally being 
saturated or mono unsaturated and might also contain a hydroxyl group on the second 
carbon (Futerman and Hannun, 2004). Sphingosine, the most abundant long chain base 
in mammals, is composed by 18-carbons with a double bond at the 4-5 position. On the 
other hand, sphinganine, that is the product of de novo synthesis, lacks this double bond. 
Other long chain bases may have different number of carbons (14-22 carbons), hydroxyl 
groups (mainly at positions 4 and 6), more than one double bond and even branching of a 
methyl group on carbon 9 (Weissmann, 1964; Merrill and Sandhoff, 2002). 
 
Glycosphingolipids (GSLs) are composed of a Cer backbone and a sugar 
headgroup. Only the eukaryotes and a few bacteria contain these heterogeneous class of 
lipids (Degroote et al., 2004; Wevers and Gieselmann, 2005; Ni et al., 2006). It is known 
that the carbohydrate residue is attached by a glycosidic linkage to O-1 of the sphingoid. 
GSLs on the cell surface are involved in cell-type specific adhesion processes and can 
function as binding sites for toxins, viruses and bacteria (Kolter and Sandhoff, 1999; 
Wevers and Gieselmann, 2005). 
 
2.2. Metabolism and transport  
 
The metabolic pathway of SLs represents a complex network of reactions in which 
the central molecule is Cer (Figure 6). This includes: the biosynthesis of Cer and GSLs 
that occurs in the ER and Golgi complex, and sequential degradation of GSLs to Cer by 
the action of specific exohydrolase in the lysosome (Wevers and Gieselmann, 2005; 
Kitatani et al., 2008). The lysosomal Cer is subsequently converted into sphingosine and 
fatty acid by the action of ACDase. Sphingosine can be transported through the lysosomal 
membrane and be used in the enzymatic conversion to Cer or sphingosine-1-phosphate 
(S1P). Additionally, Cer can be formed from SM by sphingomyelinase action. In the case 
of ASMase, the enzyme is present in endosomes/lysosomes of all cells (Wevers and 
Gieselmann, 2005; Kitatani et al., 2008). 
 
Pathways of SL metabolism have a unique metabolic entry point, serine palmitoyl 
transferase (SPT), which forms the first SL in the de novo pathway, and a unique exit 
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point, S1P lyase, which breaks down S1P into non-SL molecules (Castino and Isidoro, 
2008; Hannun and Obeid, 2008).  
 
 
Figure  6 - The central position of Cer in SL metabolism 
Cer can come from de novo synthesis due to stimulation of SPT and/or dihydroceramide synthase, or by degradation of 
sphingomyelins via spingomyelinases. It can also be generated through metabolism of complex SLs. A major metabolite of 
ceramide is ceramide-1-phosphate (C1P), which can be formed through direct phosphorylation of ceramide by ceramide 
kinase. The reverse reaction is catalyzed by ceramide-1-phosphate phosphatase, or by lipid phosphate phosphatases. 
There is increasing evidence suggesting that C1P can regulate cell proliferation and apoptosis. Alternatively, Cer can be 
degraded by ceramidases to form sphingosine, which can, in turn, be phosphorylated to S1P by sphingosine kinases. The 
reverse reaction is catalyzed by S1P phosphatases, or by lipid phosphate phosphatases. SM N-deacylase generates 
sphingosylphosphorylcholine. Bioactive SL metabolites are highlighted in red. SPT, serine palmitoyl transferase; KDS, 3-
keto-dihydrosphingosine reductase; DES, dihydroceramide desaturase; SPPase, Sph phosphate phosphatase; CK, Cer 
kinase; C1PP, C1P phosphatase; SMS, SM synthase; PC, phosphatidylcholine; DAG, diacylglycerol; GCS, 
glucosylceramide synthase; GCase, glucosyl CDase. (Taken from Bartke and Hannun, 2009) 
 
 
f r specific c ain length fatty acyl CoAs. CerS1, for xam-
ple, shows significant pref r ce for C18:0 FA CoA, wher as
CerS5 and C rS6 preferably catalyze the acylati n of (dh)
Sph with myris oyl-, palmitoyl , and stearoyl-CoA c mpared
with very lon -chain FA CoAs (11). dhCer is then desatu-
ted by dhCer de aturase, generating a 4,5-trans-double
bond to form Cer (12).
In the foll w ng SL biosynth tic reactions, Cer i primar-
ily us d for the synthesis of SM by transferring a ospho-
choline headgroup from phosphatidylcholine through the
action of SM synthases, ther by also generati g diacyl-
glycerol (13).
Cer can also be phosphorylated by Cer kinase, which in
turn can be recycled by a C1P phosphatase (14) or glyco-
sylated by glucosyl or galactosyl Cer synthases (15).
In the hydrolytic pathway, SM is cleaved by one of
several sphingomyelinases (SMases), releasing phospho-
choline and Cer. The SMases can be distinguished ac-
cording to their pH optima and subcellular localization.
Several SMases have been characterized: lysosomal acid
SMase (aSMase), zinc-dependent secretory SMase, neutral
magnesium-dependent SMase (nSMase), and alkaline
SMase (16).
Another important source of Cer is provided by the
breakdown of glycosphingolipids through sequential re-
moval of their terminal hydrophilic portions catalyzed by
a series of specific hydrolases. The products glucosylcer-
amide (GlcCer) and galactosylceramide are subsequently
hydrolyzed by specific b-glucosidases and galactosidases
to release Cer (17).
C r is metabolized by ceramidases (CDases), removing
the amide-linked FA to form Sph. Three types of CDases
have be n classified by their pH optimum and subcellular
localization: acid CDase, neutral/alkaline CDase, and alka-
line CDase (18). Sph is then available for recycling into SL
pathw ys or for phosphorylation by one of two Sph kinases,
SK1 and SK2, to form S1P (19). In return, S1P phosphatases
dephosphorylate S1P regenerating Sph (20). Finally, S1P
lyase can m tabolize S1P to release ethanolamine phos-
phat and hexadecenal (21).
COMPARTMENTALIZATION AND REGULATION OF
BIOACTIVE SLS
Enzymatic reactions in SL metabolism are distributed
throughout different cellular compartments (Fig. 2). Un-
derstanding the functions of SLs requires insight into the
specific subcellular localization of the enzymes involved in
the SL pathway. The initial steps of SL de novo synthesis
leading to Cer formation take place on the cytosolic sur-
face of the endoplasmic reticulum (ER) and potentially
in ER-associated membranes, such as the perinuclear mem-
brane and mitochondria-associated membranes (12). Syn-
thesis of more complex SL metabolites like SM and GluCer
occurs in the Golgi apparatus. Two specific pathways are
known for the transport of Cer from the ER to the Golgi.
First, SM is formed of Cer provided by the Cer transfer
protein, CERT. Second, the synthesis of GluCer is based
on Cer deriving from vesicular transport. Subsequently,
Fig. 1. Scheme of SL metabolism. Pathways are
shown as described in the text. Bioactive SL metabo-
lites are highlighted in red. SPT, serine palmitoyl
transferase; KDS, 3-keto-dihydrosphingosine reduc-
tase; DES, dihydroceramide desaturase; SPPase, Sph
phosphate phosphatase; CK, Cer kinase; C1PP, C1P
phosphatase; SMS, SM synthase; PC, phosphatidyl-
choline; DAG, diacylglycerol; GCS, glucosylceramide
synthase; GCase, glucosyl CDase.
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2.3. Function 
 
As mentioned above, SLs are found in essentially all animals, plants, and fungi, as 
well as some prokaryotic organisms and viruses. They are mostly in membranes, but are 
also major constituents of lipoproteins. The functions of SLs are still being discovered, but 
there are at least three, i.e., structure, recognition and signal transduction (Merrill and 
Sandhoff, 2002; Wevers and Gieselmann, 2005). Besides the role in membrane and 
lipoprotein structure, they also act in cell regulation as second messengers for growth 
factors, differentiation factors and cytokine. SLs have also been implicated in intracellular 
signaling, modulating a variety of events such as cell-cell interaction, proliferation, 
differentiation, cell death, and stress responses (Futerman and Hannun, 2004; Kacher 
and Futerman, 2006; Castino and Isidoro, 2008).  
 
3. Lysosomal Storage Disorders: Sphingolipidoses  
 
Was Hers who introduced in 1965 the concept of "lysosomal storage disorders"  
(LDSs) to explain how genetically determined absence of a seemingly unimportant 
enzyme, α-glucosidase, could lead to the fatal condition known as Pompe disease (Hers, 
1965; Neufeld, 1991; Wevers and Gieselmann, 2005). After this, a series of important 
discoveries were made, regarding intracellular biology of these enzymes and their 
substrates, that culminated on the successful treatment of Gaucher's disease through 
enzyme replacement therapy with β-glucosidase in the early 1990s (Jmoudiak and 
Futerman, 2005).  
 
LSDs, of which more than 50 are known (Table 1), are a heterogeneous group of 
inherited metabolic neurodegenerative disorders due to deficiency of a specific protein 
required for lysosomal function, such as enzymes or lysosomal components, or to errors 
in enzyme trafficking/targeting that are involved in lysosomal biogenesis or protein 
maturation, all preventing the complete degradation and recycling of macromolecules, 
which results in the intra-lysosomal accumulation of undegraded metabolites (Alberts et 
al., 2002; Futerman and Van Meer, 2004; Mehta et al., 2006; Bellettato and Scarpa, 
2010). This is determined by the specific mutation(s) that an individual carries and the 
effect of that specific mutant genotype on enzyme stability and/or function. The majority of 
LSDs are inherited in an autosomal recessive fashion, except for three disorders: Fabry 
disease, Dannon disease, and Hunter syndrome (Mucopolisacaridosis type II) that are all 
X-linked recessive (Alberts et al., 2002; Greiner-Tollersrud and Berg, 2005; Pastores, 
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2011). Almost invariably, heterozygotes with 50% enzymatic activity do not develop the 
disease, a notable exception being some female carriers of the X-linked disorder Fabry 
disease (Jeyakumar et al., 2005; Wevers and Gieselmann, 2005). 
 
The importance of a physiologically appropriate SL catabolism is demonstrated by 
the severity of sphingolipidoses. In these diseases, mutations in genes encoding acid 
hydrolases or protein cofactors, cause a blockage in specific steps of the lysosomal 
degradation pathway of SLs (Futerman and Van Meer, 2004; Saftig and Klumperman, 
2009). 
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2. Table  1 – Some of LSDs (Taken from Futerman and van Meer, 2004) 
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Table 1 | Lysosomal storage disorders*
Disease Defective protein Main storage materials
Sphingolipidoses
Fabry α-Galactosidase A Globotriasylceramide and blood-group-B 
substances
Farber lipogranulomatosis Ceramidase Ceramide
Gaucher β-Glucosidase Glucosylceramide
Saposin-C activator Glucosylceramide
Niemann–Pick A and B Sphingomyelinase Sphingomyelin
Sphingolipid-activator deficiency Sphingolipid activator Glycolipids
GM1 gangliosidosis β-Galactosidase GM1 ganglioside
GM2 gangliosidosis (Tay–Sachs) β-Hexosaminidase A GM2 ganglioside and related glycolipids
GM2 gangliosidosis (Sandhoff) β-Hexosaminidase A and B GM2 ganglioside and related glycolipids
GM2 gangliosidosis (GM2-activator deficiency) GM2-activator protein GM2 ganglioside and related glycolipids
Mucopolysaccharidoses (MPS)
MPS I (Hurler, Scheie, Hurler/Scheie) α-Iduronidase Dermatan sulphate and heparan sulphate
MPS II (Hunter) Iduronate-2-sulphatase Dermatan sulphate and heparan sulphate
MPS IIIA (Sanfilippo) Heparan N-sulphatase (sulphamidase) Heparan sulphate
MPS IIIB (Sanfilippo) N-Acetyl-α-glucosaminidase Heparan sulphate
MPS IIIC (Sanfilippo) Acetyl-CoA:α-glucosamide Heparan sulphate
N-acetyltransferase
MPS IIID (Sanfilippo) N-Acetylglucosamine-6-sulphatase Heparan sulphate
Morquio-A disease N-Acetylgalactosamine Keratan sulphate, chondroitin-6-sulphate
-6-sulphate-sulphatase
Morquio-B disease β-Galactosidase Keratan sulphate
MPS VI (Maroteaux–Lamy) N-Acetylgalactosamine-4-sulphatase Dermatan sulphate
(arylsulphatase B)
MPS VII (Sly) β-Glucuronidase Heparan sulphate, dermatan sulphate,
chondroitin-4- and -6-sulphates
Oligosaccharidoses and glycoproteinosis
Pompe (glycogen-storage-disease type II) α-Glucosidase Glycogen
Diseases caused by defects in integral membrane proteins
Cystinosis Cystinosin Cystine 
Danon disease LAMP2 Cytoplasmic debris and glycogen
Infantile sialic-acid-storage disease and Sialin Sialic acid
Salla disease
Mucoplipidosis (ML) IV Mucolipin-1 Lipids and acid mucopolysaccharides
Niemann–Pick C (NPC) NPC1 and 2‡ Cholesterol and sphingolipids
Others
Galactosialidosis Cathepsin A Sialyloligosaccharides
I Cell and pseudo-Hurler polydystrophy (ML II UDP-N-acetylglucosamine:lysosomal Oligosaccharides, mucopolysaccharides
and ML III, respectively)§ enzyme N-acetylglucosaminyl-1- and lipids
phosphotransferase
Multiple sulphatase deficiency Cα-formylglycine-generating enzyme Sulphatides
Neuronal ceroid lipofuscinosis CLN1 (protein palmitoylthioesterase-1) Lipidated thioesters
(NCL)1 (Batten disease)||
NCL2 (Batten disease) CLN2 (tripeptidyl amino peptidase-1) Subunit c of the mitochondrial ATP synthase
NCL3 (Batten disease) Arginine transporter Subunit c of the mitochondrial ATP synthase
*This table shows lysosomal storage disorders (LSDs) that are discussed in this article. For a complete list of LSDs, please see online supplementary information S1
(table). Detailed information about each disease can be obtained from REF. 108, and complementary lists of LSDs can be found in REFS 89,109. The prevalence of some
of LSDs has been studied in a pan-ethnic Australian population110, which does not specifically address ethnic groups in which some of the diseases are more
prevalent. ‡NPC1 might transport cholesterol. Alternatively, it might be involved in sphingolipid homeostasis53. The related NCP1-like protein-1 (NPC1L1), which
contains a similar sterol-sensing domain to NPC1, is involved in cholesterol absorption in intestinal cells111. NPC1 and the cholesterol-binding NPC2 in the lysosome
lumen might function together112. § ML II and ML III were originally classified as mucolipidoses, but they are now known to be caused by the defective transport of
lysosomal enzymes to lysosomes in cells of mesenchymal origin, rather than by a defect in lysosomal lipases. ||There are at least eight classes of NCL16, but the
function of the defective proteins is only known for NCL1, 2 and, possibly, 3 (REF. 22). LAMP2, lysosome-associated membrane protein-2. 
© 2004 Nature Publishing Group
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Sphingolipidoses are a group of inherited disorders of lipid metabolism affecting the 
central nervous system (CNS). Mostly affecting pediatric population, these diseases are 
characterized by progressive involvement of neurons, with psychomotor retardation. 
However, this is a heterogeneous group of diseases and the diagnosis on clinical groups 
is oftentimes difficult. Niemann-Pick disease, Krabbe's disease, Gaucher's disease, 
Metachromatic leukodystrophy, Tay-Sachs disease, and generalized gangliosidosis, are 
examples of sphingolipidoses (Brady, 1978; Luzio et al., 2000). Sphingolipidoses are due 
to an impaired lysosomal digestion of GSLs metabolism. GSLs are degraded by the action 
of exohydrolases and in some cases by SL activator proteins. Until now there are five SL 
activator protein (SAPs), the SAP-A to D also called saposins and the GM2-activator 
(Kolter and Sandhoff, 1998; Luzio et al., 2007).  
 
Even though, separately, these disorders are rare, when considered all together 
their prevalence is much higher, 1 in 5000 children will be found to have an LSD, caused 
primarily by a deficiency of a lysosomal hydrolase or its cofactor (Lefrancois et al., 2003; 
Mari et al., 2008; Pastores, 2011). Certain disorders have higher prevalence in specific 
geographic areas or among those of a particular ethnicity. In terms of geographic areas 
aspartylglucosaminuria and Salla disease, are particularly frequent in Finland; in terms of 
ethnicity, Gaucher and Tay-Sachs disease, are almost 100 times more prevalent in 
Ashkenazi Jewish descendant that in the general population (Lefrancois et al., 2003; 
Westergaard et al., 2004; Greiner-Tollersrud and Berg, 2005). In Portugal, for example, 
the overall birth prevalence of 29 different LSDs studied was calculated to be 25/100 000 
live births, which is double the prevalence that has previously been described in Australia 
and in The Netherlands (Meikle et al., 1999; Poorthuis et al., 1999; Pinto et al., 2004; 
Braulke and Bonifacino, 2009). 
 
3.1. Diagnosis 
 
In sphingolipidoses a wide spectrum of clinical phenotypes is observed, with 
differences in the age of onset, clinical severity or neurological involvement, and typically 
has a neurodegenerative course (Beck, 2001; Jeyakumar et al., 2005; Braulke and 
Bonifacino, 2009). In general, neuropathological symptoms include developmental delay, 
abnormal ocular movements, ataxia, seizures, movement disorders, spasticity, visual loss 
and psychiatric disease (psychosis, depression and dementia). Although most 
sphingolipidoses have onset in childhood, several subtypes have later-onsets with 
symptoms that may not be evident until adulthood. One of the main factors that determine 
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the severity of a LSD, such as Sandhoff or Tay–Sachs disease, is the residual activity of 
the affected enzyme (Conzelmann and Sandhoff, 1983; Kornfeld and Mellman, 1989). 
Thus, the best known predictor of age of onset and clinical course of the diseases is the 
level of residual enzyme activity (Jeyakumar et al., 2005; Luzio et al., 2007). This is 
determined by the specific mutation(s) carried by each individual. The diagnosis in 
suspected cases can be confirmed by biochemical and/or molecular assays, which can be 
applied for prenatal and presymptomatic diagnosis (Alberts et al., 2002; Greiner-
Tollersrud and Berg, 2005; Pastores, 2011). Early diagnosis and intervention before the 
onset of irreversible pathology will provide a substantial benefit to many of these 
newborns, as well as providing the opportunity for parents to receive genetic counseling. 
Thus, prevalence data are important to delineate prevention and therapeutic strategies 
(Luzio et al., 2000; Pinto et al., 2004; Luzio et al., 2007).  
 
3.2. Molecular Pathogenesis 
 
As mentioned above, a wide spectrum of clinical phenotypes is observed, with 
differences in the age of onset, clinical severity or neurological involvement, and typically 
has a neurodegenerative course (Nixon and Cataldo, 1993; Beck, 2001; Jeyakumar et al., 
2005). In sphingolipidoses, as for all the other LSDs, the undegraded substrate gradually 
accumulates within lysosomes. However, it is now recognized that these disorders are not 
simply a consequence of pure storage, but result from perturbation of complex cell 
signaling mechanisms where the different mutations have different effects on the enzyme 
stability and/or function and, consequently, different biological outcome (de Duve and 
Wattiaux, 1966; Vellodi, 2005). The relationship between genotype and phenotype at the 
level of disease process remains poorly defined and, for most storage disorders, this is 
only an approximate guide to clinical outcome (Walkley, 1998; Luzio et al., 2000; 
Jeyakumar et al., 2005). The appearance of these diseases could presumably occur due 
to the defective activity of one or more of the enzymes involved in the degradative 
pathway, and consequently leading to changes in the balance between specific SL 
signaling molecules, causing effects on cell function and survival (Kolter and Sandhoff, 
1999; Nixon, 2007) (Figure 7).  
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Figure  7 - Mechanism of LSDs (Taken from Settembre et al., 2013). 
 
 
3.2.1 Apoptosis 
 
Programmed cell death occurs primarily through an evolutionarily conserved form of 
cell suicide called apoptosis (Storrie and Desjardins, 1996; Vaux, 1998; Luzio et al., 2000; 
2007). In apoptosis, a biochemical cascade activates proteases that destroy molecules 
that are required for cell survival and others that mediate a program of cell suicide 
(Friedlander, 2003). This event occurs In multicellular organisms and it is important for cell 
homeostasis maintained through a balance between cell proliferation and cell death 
(Vaux, 1998). Apoptosis can be induced in several cell types by tumor necrosis factor 
(TNF), anti-fas antibody, radiation and chemotherapeutic agents such as actinomycin D, 
through generation of Cer by activation of the sphingomyelinase pathway or ceramide 
synthase (Hannun, 1996; Tohyama et al., 1999). This simple SL can act as an intracellular 
mediator of cell growth, differentiation and apoptosis (Hannun, 1996; Tohyama et al., 
1999). In the lysosome, ASMase induces Cer release (Hannun and Luberto, 2000). 
However, the mechanisms of ASMase/Cer-mediated death signaling are not completely 
clear. In stress conditions, such as defective activity of lysosomal proteins, which results 
in the intra-lysosomal accumulation of undegraded metabolites, the apoptotic cascade can 
be activated (Futerman and Van Meer, 2004). Previous work showed exacerbated 
apoptosis in cells or tissues from patients or animals affected with neurolipidoses, Tay–
Sachs and Sandhoff (Tardy et al., 2004). Thus lysosomal dysfunction may affect 
Nature Reviews | Molecular Cell Biology
Mutations of lysosomal hydrolases,
lysosomal membrane proteins or
non-lysosomal proteins
Primary storage
(for example,
GAGs, glycogen)
Secondary storage
(for example, lipids)
Lysosomal dysfunction Pathogenic
cascades
rCa2+ defects
rImpaired signalling
rLysosomal membrane
   permeabilization
Autophagy impairment
Tertiary storage
(cytosolic autophagic substrates)
Pathogenic
cascades
Gaucher’s disease
An autosomal recessive 
lysosomal storage disorder 
due to the deficient activity 
of β-glucocerebrosidase.
Current therapeutic strategies for LSDs are aimed at 
either restoring or replacing the activity of defective lyso-
somal enzymes, and they involve molecular chaperones, 
enzyme replaceme t or viral-mediated gene therapy158. 
Inhibition of substrate synthesis is another available 
thera peutic option for some LSDs158. These strategies, 
however, have limitations, such as the difficulty of tar-
geting the enzyme, or the gene, to the required sites in the 
body. For i stance, a major hurdle for delivering therapies 
to the brain is the difficulty that these enzymes encoun-
ter in crossing the blood–brain barrier. Considering that 
LSDs include over 60 different diseases and that in most 
cases each therapy is strictly disease-specific, the over-
all costs of preclinical studies and clinical trials will be 
extremely high.
Accumulating evidence indicates that lysosomal and 
autophagy dysfunction is one of the main mechanisms 
underlying common neurodegenerative diseases such as 
Parkinson’s disease, Alzheimer’s disease and Huntington’s 
disease159,160 (FIG. 3). Mutated aggregate-prone protein s 
that cause neurodegenerative diseases, such as expanded 
huntingtin (HTT) in Huntington’s disease and mutated 
α-synuclein in Parkinson’s disease, are cleared by 
boosting the lysosomal–autophagic pathway161–163. 
In addition, aggregate-prone proteins may in turn 
affect the efficiency of autophagy by inhibiting cargo 
recognitio n by autophagosomes164,165.
Mutations in genes encoding essential components 
of the endolysosomal—autophagic pathway have also 
been described in several neurodegenerative diseases. 
A significant number of patients with Parkinson’s diseas e, 
particularly among Ashkenazi Jews166, are hetero zygous 
for mutations in the gene encoding the lysosomal 
enzyme β-glucocerebrosidase167. Homozygous muta-
tions in the same gene cause Gaucher’s disease, a neuro-
degenerative LSD168. It has been proposed that lower 
levels of β-glucocerebrosidase lead to an increased 
accumulation of glucosylceramide in the lysosome, and 
this in turn accelerates the synthesis and stabilization 
of soluble α-synuclein oligomers that eventually conv rt 
into amyloid fibrils. Furthermore, the accumulation of 
α-synuclein also blocks the trafficking of newly synthe-
sized β-glucocerebrosidase to the lysosome and thus 
further amplifies glucosylceramide accumulation169. 
In addition, mutations in ATPase type 13A2 (ATP13A2), 
a component of the lysosomal acidification machinery, 
were found in patients ith her ditary arkinsonism170 
and are associated with lysosomal dysfunction, defective 
Box 3 | Mechanisms of lysosomal storage diseases (LSDs)
.5&UCTGCITQWRQHTCTGCPFTGEGUUKXGN[KPJGTKVGFOGVCDQNKEF[UHWPEVKQPUYKVJCPQXGTCNNKPEKFGPEGQHKP.5&UCTG
caused by mutations of genes encoding proteins that localize to the lysosomal lumen, lysosomal membrane or other 
cellular compartments that contribute to lysosomal function. These disorders are characterized by the progressive 
accumulation of material that has not been degraded in the lysosomes of most cells and tissues. Approximately 60 
FKHHGTGPVV[RGUQH.5&UJCXGDGGPTGEQIPK\GF*KUVQTKECNN[.5&UJCXGDGGPENCUUKHKGFQPVJGDCUKUQHVJGV[RGQHOCVGTKCN
that accumulates in the lysosomes, such as mucopolysaccharides, sphingolipids, glycoproteins, glycogen and lipofuscins. 
.5&UQHVGPUJQYCOWNVKU[UVGOKERJGPQV[RGVJCVKUCUUQEKCVGFYKVJUGXGTGPGWTQFGIGPGTCVKQPOGPVCNFGENKPGEQIPKVKXG
RTQDNGOUCPFDGJCXKQWTCNCDPQTOCNKVKGU1VJGTVKUUWGUVJCVCTGEQOOQPN[CHHGEVGFCTGDQPGCPFOWUENG%GNN|CPFVKUUWG
pathology are the result of a complex series of pathogenic cascades that occur downstream of lysosomal dysfunction. 
6JG|HKIWTGKNNWUVTCVGUVJGOCKPUVGRUWPFGTN[KPI.5&RCVJQIGPGUKU/WVCVKQPUKPIGPGUVJCVCTGKORQTVCPVHQTN[UQUQOCN
function result in the accumulation of specific substrates that have not been degraded in the lysosome (primary storage). 
This leads to the accumulation of additional lysosomal substrates (secondary storage) due to a blockage in lysosomal 
VTCHHKEMKPI'ZEGUUKXGN[UQUQOCNUVQTCIGJCUCDTQCFKORCEVQPN[UQUQOCNHWPEVKQPD[ECWUKPIFGHGEVUKP%C2+|JQOGQUVCUKU
UKIPCNNKPICDPQTOCNKVKGUCPFN[UQUQOCNOGODTCPGRGTOGCDKNK\CVKQP+PCFFKVKQPN[UQUQOCNF[UHWPEVKQPKUCUUQEKCVGFYKVJ
autophagy impairment, due to defective fusion between lysosomes and autophagosomes. This causes the accumulation 
of autophagic substrates such as aggregate-prone proteins and dysfunctional mitochondria (tertiary storage), which 
contributes to neurodegeneration. GAGs, glycosaminoglycans.
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apoptosis, either stimulation or reduction through different potential mechanisms (Tardy et 
al., 2004). 
Levade and co-workers (Tardy et al., 2004) enumerated some of this possible 
mechanisms: 
1) Accumulation of a toxic compound, due to its deficient breakdown, 
galactosylsphingosine, which accumulates in Krabbe disease, is an example for 
this mechanism.  
2) Lack of formation of a molecule acting as an apoptosis inducer; defect in the 
lysosomal hydrolase may result in an impaired formation of Cer in the acidic 
compartments or in the PM, this happens in Niemann–Pick disease (NPD).  
3) Lack of a molecule acting as an apoptosis suppressor; an example is prosaposin 
that results in activation of mitogen-activated protein kinases leading to 
(pro)saposin deficiency, or CLN3,  which attenuates Cer formation, leading to a 
form of juvenile neuronal ceroid lipofuscinosis (NCL). 
4) Deficient activity of a protease in the lysosomal compartment; leading to the 
absence of proteolytic processing of a protein involved in apoptosis, it is caused by 
deficient activity of cathepsin C, which is the responsible for defective processing 
of granzymes, this syndrome is called Papillon–Lefèvre.  
5) Deficient activity of a lysosomal protease that is potentially active outside the 
acidic compartments, cathepsins D or B may activate the caspase cascade. 
6) Uncontrolled activation of lysosomal proteases and excessive proteolysis, due, for 
instance, to the lack of a cathepsin inhibitor. One example is cystatin B, a cysteine 
protease inhibitor; when this gene is mutated causes Unverricht–Lundborg 
disease.  
7) Abnormal signal transduction of apoptotic signals due to a general perturbation of 
intracellular trafficking related to dysfunction of lysosomal catabolism. This 
situation could happen in cells of mucolipidosis type II and III. 
 
 
Many reports indicate that Cer generation by sphingomyelinase is an important 
physiological cause of apoptosis (Tohyama et al., 1999). However some controversial 
observations have been reported regarding apoptosis induction in cells or tissues from 
NPD or FD. ASMase deficiency has been associated with resistance, in certain cell types, 
to programmed cell death triggered by ionizing or ultraviolet radiation, TNF, doxorubicin, 
or CD95 ligation (Peña et al., 1997; Canals et al., 2011), while defective in ACDase 
appeared to be linked with an increased apoptosis in colon (Canals et al., 2011). Other 
rare lysosomal disorders characterized by multiple substrate storage, are mucolipidoses. 
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Previous studies indicated that apoptosis is disturbed in these diseased cells. According 
to these findings that support the idea that lysosomal components are involved in 
apoptosis, in the presence of lysosomal dysfunction, cell-death program is compromised 
(Tardy et al., 2004). 
 
3.2.2 Inflammation 
Inflammation can be defined as an active defense reaction of multicellular 
organisms against diverse insults, designed to remove or inactivate noxious agents and to 
inhibit and reverse their detrimental effects (Wyss-Coray and Mucke, 2002). The 
catabolism of macromolecules in the lysosome is essential for the correct function of 
several immune system functions including antigen processing and presentation, cytokine 
secretion, phagocytosis, and secretion of molecules (Castaneda et al., 2008). The 
inflammation can results as a consequence of storage material disturbs in cellular function 
(Beck, 2010). Previous studies showed abnormal inflammatory responses in the brain in 
LSDs, such as, in glycosphingolipidoses, gangliosidoses, Sandhoff disease, and in all 
types of NCLs (Castaneda et al., 2008). The mechanisms leading to immune activation 
are not completely known, but probably reflect altered signaling pathways in response to 
storage (Vitner et al., 2010). In LSDs with CNS involvement, brain inflammation is a 
common feature (Smith et al., 2009; Vitner et al., 2010). After substrate accumulation in 
LSDs, an inflammatory response is triggered that is not self-limiting, and once triggered, it 
progressively increases in parallel with the storage burden (Vitner et al., 2010). Previous 
studies showed in the CNS of a Sandhoff disease mouse model and in a Sandhoff 
disease human autopsy, macrophage/ microglial activation, which was implicated in 
neuro-inflammatory component in this disorder (Jeyakumar et al., 2003). In GM1 and GM2 
gangliosidoses, which store GM1 and GM2 ganglioside respectively, the activation of both 
CNS and peripheral inflammation predates the onset of clinical signs and involves 
elevation of multiple proinflammatory cytokines (Vitner et al., 2010). Thus, lysosomal 
storage causes immune activation by different molecular mechanisms depending on 
where storage occurs and on the biochemical nature of the stored molecules (Vitner et al., 
2010). This allows the relationship between degree of inflammation, storage levels and 
pathology to be correlated (Jeyakumar et al., 2003). Once neuro-inflammation can be a 
key player in the pathogenic process, effective therapies in multiple LSDs would be 
predicted to impact this process and delay inflammation (Jeyakumar et al., 2003). One 
example was a mouse model of Sandhoff disease treated with non-steroidal anti-
inflammatory drugs or crossed with the MIP1 alpha knock-out mouse to prevent peripheral 
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immune cell recruitment to the brain, resulting in clinical benefit. This benefit was also 
observed for mouse model of NPC1 (Vitner et al., 2010).  
 
3.2.3 Autophagy 
Cell death is usual classified into two groups, necrosis, a passive, uncontrolled way 
to die, and programmed cell death, which consists in a highly regulated process with 
defined cellular pathways. Programmed cell death was categorized into three types, 
according to the basis of morphological features, they include, the type 1 which is 
apoptosis; type 2, autophagy; and finally type 3, that is a nonlysosomal cell death. 
Autophagic cell death it has often been proposed to be an alternative mechanism of 
programmed cell death (Debnath et al., 2005). 
 
The autophagic process was first described in mammalian cells many years ago 
(Baba et al., 1994) It represents an evolutionary mechanism conserved in eukaryotic cells 
where the lysosomal degradation pathway for cytoplasmic material is preceded by the 
formation of an AP, enclosed within a double membrane that engulfs part of the cytoplasm 
by fusing with endocytic compartments and lysosomes (Codogno and Meijer, 2005; 
Kiselyov et al., 2007). The latter ones are essential for maturation and completion of 
autophagy-initiated protein and organelle degradation (Kiselyov et al., 2007). This 
ubiquitous process can be stimulated in response to stress conditions, allowing the cell to 
adapt to environmental and/or developmental changes (Klionsky, 2007).  
 
Three general types of autophagic processes have been identified in eukaryotic 
cells, named macroautophagy, microautophagy and chaperone-mediated autophagy. 
However the best-studied of these pathways is macroautophagy, which is linked to a 
range of human disease (Huang and Klionsky, 2007). Recent research suggests the 
defect in autophagic process may be a characteristic of a group of neurodegenerative 
diseases referred to as LSDs (Winslow and Rubinsztein, 2008). Without this fusion event 
APs accumulate with undegraded cargo, thus increasing the toxic species within cells 
(Winslow and Rubinsztein, 2008). Autophagy has been analyzed in a variety of LSDs with 
different phenotypic severities, different tissues involved, and different types of storage 
material. Previous studies suggested that an accumulation of one or more GSLs may alter 
the function of the autophagic pathway in these disorders (Lieberman et al., 2012). 
Another study suggested that lysosomal deficiencies in LSDs inhibit autophagic 
maturation, leading to a condition of autophagic stress (Kiselyov et al., 2007). Thus, a 
common factor can be the impairment of autophagy and accumulation of autophagy 
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substrates in LSDs. This observation suggests that at least some mechanisms underlying 
the LSD phenotype may be similar to other diseases in which defective autophagy have 
been observed (Lieberman et al., 2012). The study of autophagy may yet lead to the 
elucidation of the mechanisms of cellular death and the development of new tailored 
therapies for these devastating disorders (Codogno and Meijer, 2005). 
 
   3.2.4. Lipid Trafficking  
SLs are essential constituents of eukaryotic cells and they are highly enriched on 
the PM. However, they are also internalized and transported to the LE and lysosomes 
where they are degraded in a stepwise fashion, culminating in the cleavage of Cer to fatty 
acid and sphingosine, as mentioned above (Pagano et al., 2000; Bartke and Hannun, 
2009). The SL metabolic pathway displays an intricate network of reactions that is 
catalyzed by a specific enzyme and in some cases assisted by helper SAPs which 
present the substrate to the hydrolytic enzyme. This process results in the formation of a 
multitude of SLs, with Cer as the center of SL biosynthesis, catabolism, and as precursors 
of complex SLs (Pagano et al., 2000; Bartke and Hannun, 2009). Mutations in either a 
hydrolase or an activator protein can lead to defective hydrolysis and intracellular 
accumulation of lipids (Pagano et al., 2000). In addition to this primary storage, secondary 
storage products can also be found in LSDs (Walkley and Vanier, 2009). The most 
ubiquitous and best studied of these secondary storage materials are GSLs and 
phospholipids, as well as Chol (Walkley and Vanier, 2009). 
 
Previous studies showed an altered lipid trafficking of SLs in some LSDs. The 
mechanism by which lipid trafficking is altered is not clear. However it can be related to 
changes in Chol levels (Vitner et al., 2010). Previous studies suggested that Chol is 
sequestered in the SL storage compartment owing to the fact that Chol and SLs physically 
associate with one another (Pagano et al., 2000; Pagano, 2003). Thus elevated Chol 
levels or altered Chol distribution are involved in the altered SL trafficking defect (Pagano, 
2003). Fluorescent lipid analogs have been used to monitor lipid accumulation in cells 
from patients with LDSs (Pagano et al., 2000).  
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3.3. Therapy 
All over the years, different therapeutic approaches were provided in patients with 
LSDs, to face the underlying consequences of the diseases. Infusion of plasma or plasma 
fractions (S Bruni, 2007), intravenous injection of exogenous enzymes extracted from 
human tissues (Brady, 2006), infusion of leukocytes and implantation of skin fibroblasts or 
amniotic cells (Yeager et al., 1985), bone marrow transplantation (BMT) (Hoogerbrugge et 
al., 1995), enzyme replacement therapy (Brady, 2006) and gene therapy (Dodge and 
Cheng, 2009) are based on this rationale and are some of the examples of therapeutic 
strategies that have been employed to ameliorate LSDs (S Bruni, 2007). Presently, 
treatment for LSDs follows two simple principles: first, the augment of the enzyme levels, 
genetic replacement or cellular complementation and, second, the partial inhibition of the 
biosynthesis rate of the parent cellular macromolecules (Cox, 2005). The substrate 
reduction therapy was first proposed by Radin in the 1970s (Cox, 2005) and then adapted 
for clinical use with particular reference to the sphingolipidoses. This treatment constitutes 
administration of small diffusible molecules that inhibit key biosynthetic steps in the 
formation of the parent substrates (Cox, 2005). 
 
 
4. Farber Disease  
 
Human ACDase (N-acylsphingosine deacylase, EC 3.5.1.23; ACDase) was 
originally identified by Gatt in 1963 in rat brain homogenates, but only in 1995 it was first 
purified from urine and characterized by Bernardo et al. (Bernardo et al., 1995). ACDase 
is the lysosomal enzyme catalyzing the hydrolysis of Cer to free fatty acid and 
sphingosine one of the final steps in SL degradation.  
 
ACDase is a glycosylated protein consisting of two subunits, an unglycosylated α-
subunit with molecular mass of 13 kDa and a N-glycosylated β-subunit with molecular 
mass of 40 kDa. These two subunits are linked by an interchain disulfide bond forming the 
polypeptide with molecular mass of 50 kDa (Koch et al., 1996). This heterodimeric 
enzyme is encoded by the ASAH1 gene located in chromosomal region 8p21.3-p22 
(Bernardo et al., 1995). Previous studies have shown the gene spans approximately 30 kb 
of DNA in the human genome and contains 14 exons and 13 introns.  
 
Mutations in the ACDase gene result in FD (Farber Lipogranulomatosis, OMIM # 
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characterized by lysosomal accumulation of Cer in most tissues, including heart, lung, 
liver, and the spleen (Sugita et al., 1972; Dulaney et al., 1976; Jameson et al., 1987; 
Kattner et al., 1997; Ehlert et al., 2007). Deficiency of ACDase was first found in FD 
patients in 1972 (Park and Schuchman, 2006). However, only in 1996 was identified the 
first mutation in the gene encoding the ACDase in a FD patient (Koch et al., 1996). After 
this, several different mutations have been found in the ASAH1 gene (Levade et al., 
2009). In 2002 was constructed the first ACDase “knock-out” mouse model by Li et al.. 
However the lifetime was very short due to the degree of severity, (Park and Schuchman, 
2006). The murine Asah1 gene resulted in early embryonic lethality (Li et al., 2002) and 
the reduction of ACDase resulted in the Cer accumulation in mouse ovaries witch led to 
apoptosis of oocytes (Eliyahu et al., 2012), reinforcing the important role of Cer in the 
apoptotic pathway (Alayoubi et al., 2013). More recently, Levade and coworkers, 
produced the first viable model of systemic ACDase deficiency via ‘‘knock-in’’ of a known 
human ASAH1 mutation [Proline (P) 362 to Arginine (R)] into a conserved murine Asah1 
gene locus (P361R) (Alayoubi et al., 2013). 
 
By electron microscopy ultrastructural abnormalities are observed, which are caused 
by the deficient activity of ACDase and stored Cer, including “elongated membranes”, 
“zebra bodies”, comma-shaped curvilinear tubules called Farber bodies, and spindle-
shaped bodies that can be detected in fibroblasts, histiocytes, and endothelial cells 
(Farber et al., 1957; Schmoeckel and Hohlfed, 1979). 
 
Diagnosis can be made by demonstrating the ACDase deficiency in vitro or else by 
showing Cer accumulation in different tissues, skin fibroblasts, white blood cells, or 
cultured amniocytes, together with impaired Cer turnover within living cells in situ (Sugita 
et al., 1972; Dulaney et al., 1976; Fensom et al., 1979; Bedia et al., 2010). 
 
4.1.  Clinical Phenotype 
 
FD was first described in 1952 by Sidney Farber (Farber, 1952). To date at least 80 
cases of Farber's disease have been reported in a variety of ethnic groups (Levade et al., 
2009). Typical symptoms of this disease are the clustering of Cer storing histiocytes and 
macrophages, which form granulomas ubiquitously. Main clinical symptoms include 
progressive, painful arthropathy, the development of subcutaneous nodules (particularly 
over the dorsal surface of joints), hoarseness induced by mechanically strained 
cutaneous, irritability, and poor growth and development which usually begins in the first 
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few months and leads to death in the first two years (Amirhakimi et al., 1976; Kattner et 
al., 1997). The clinical diagnosis is usually made during the first year of life, and the 
symptoms start at this stage. Usually death occurs during the first few years (Ehlert et al., 
2007). 
 
Clinical subtypes have been distinguished based on the age of onset, mean age of 
death and the degree of neurologic involvement (psychomotor deterioration) (Levade et 
al., 1995). According to the age of onset, the severity of the symptoms and the affected 
tissues, Farber's disease phenotype can be divided into seven different subtypes (Table 
2). 
 
Subtypes 1 to 5 are caused by the deficient activity of ACDase, and differ with 
respect to severity and sites of major tissue involvement. Subtype 6 seems to be an ill-
fated combination of subtype 1 of FD and Sandhoff disease (Fusch et al., 1989). And 
finally subtype 7, is caused by the deficiency of the sphingolipid activator protein precursor 
(prosaposin, pSAP) (Schnabel et al., 1992). Thus, FD can be differentiated into two 
groups and six subtypes according to the phenotype and clinical symptoms (Scriver, 
1995; Levade et al., 1995):   Group I, has unfavorable prognosis and often shows hepatic 
and less frequently, splenomegaly in the neonatal period. Death usually occurs within the 
first 14 months of life, subtype 4 belongs to this group for example. Group II with a less 
severe course of the disease shows less visceral involvement and only slight affection of 
the brain (Kattner et al., 1997). The usual onset is before the age of 1 year. Children with 
significant neurological involvement usually die early in infancy, whereas patients without 
or only mild neurological findings suffer from progressive joint deformation and 
contractures, subcutaneous nodules, inflammatory, periarticular granulomas, a hoarse 
voice and finally respiratory insufficiency caused by granuloma formation in the respiratory 
tract and interstitial pneumonitis leading to death in the third or fourth decade of live 
(Sugita et al., 1972; Ferlinz et al., 2001).  
  
Type 1 FD affects the majority of patients (~50% of reported cases) and is the 
classical form of the disorder. These patients normally die in the first or second year of life 
(Levade et al., 2009). These patients show signs of nervous system dysfunction that 
include impaired psychomotor development, mild retardation and peripheral nerve 
involvement (Yeager et al., 2000; Ehlert et al., 2007). 
 
Type 2 and 3, do not have so severe symptoms in CNS, when compared with type 
1, however they are still severely affected with granulomatous inflammation which leads to 
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the formation of subcutaneous nodules, joint pain and contractures, hoarseness and 
respiratory insufficiency (Devi et al., 2006). 
 
Type 4, is a very severe form with patients displaying neurological deterioration, 
extreme hepatosplenomegaly at birth and granulomatous infiltrations in the liver, spleen, 
lymphoid tissue, thymus and lungs with death in the first years of life (Antonarakis et al., 
1984). 
 
Type 5 involves progressive CNS dysfunction starting in the first 2 years of life and 
patients develop loss of speech, seizures, mental retardation, tetraplegia and myoclonia 
(Ferlinz et al., 2001).  
 
Type 6 is a combination of FD and Sandhoff disease (an LSD caused by deficiency 
of hexosaminidase A and B) (Sugita et al., 1972). This patient present hoarseness, stridor 
(noisy breathing), scattered skin nodules, painful swelling of hand joints and ankles, and 
cherry-red macular spots (Sugita et al., 1972). 
 
Type 7 FD is a single report and displays a very severe phenotype (Scriver 1995) 
that is not due to mutations in the ASAH1 gene but in the pSAP-D gene whose protein 
products enhance the activities of lysosomal enzymes (Schnabel et al., 1992; Scriver, 
1995). As a result, this patient showed combined deficiency of glucocerebrosidase, 
galactocerebrosidase and ceramidase (Schnabel et al., 1992). 
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Table  2 - Clinical phenotypes of FD patients (Taken from Levade et al., 2009). 
 
 
 
4.2. Genetic basis of the disease 
 
The first cloning of the human ASAH1 gene was made in 1999 (Park and 
Schuchman, 2006). Since then, 23 different mutations have been identified in the ASAH1 
gene of Farber patients, most of them missense mutations (Table 3). These mutations are 
distributed along 14 exons and can affect both subunits (Bär et al., 2001; Levade et al., 
2009; Muranjan et al., 2012; Alves et al., 2013).  
 
 
 
 
1 2 3 4 5 6 7
(Classical) (Intermediate) (Mild) (Neonatal) (Neurologic Progression)
(Comb 
Sandhoff)
(Prosaposin 
Deficiency)
Number of 
cases 35 14 11 6 7 1 4
Mean age 
(years)
Onset 0.3 0.66 1.6 0 1.66 0.13 0
Death 1.45 6.25 15.8 0.16 3.6 1.1 0.3
Last 
follow-up 1.1 5.6 13.0 — 3.9 — —
Nodules 100% 100% 100% 1/3 7/7 1/1 0/2
Joint 
involvement 100% 100% 100% 2/3 7/7 1/1 0/2
Hoarseness 100% 100% 100% 0/3 6/6 1/1 0/2
Large liver 14/20 3/7 3/7 100% 1/5 1/1 2/4
Large 
spleen 7/15 3/7 3/7 100% 1/5 1/1 2/4
Lung 
infiltrates 16/19 1/8 2/11 — 0/4 0/1
Macular
cherry-red 
spot
4/15 0/6 0/9 — 3/4 0/1 0/2
Lower
motor
neuron 
involvement
11/13 2/5 2/4 — 1/1 — —
Central
nervous 
impaired
15/22 3/10 5/9 — 7/7 1/1 2/4
The phenotypes identified have been subdivided further into seven subtypes. Types 1 through 5 differ with
respect to severity and sites of major tissue involvement. Type 6 is probably an ill-fated combination of
type 1 Farber disease and Sandhoff disea .2  Type 7 was represented initially by 1 patient and a
20-week fetal sibling with combined deficiencies of glucocerebrosidase, galactocerebrosidase, and
ceramidase activities3  that were subsequently shown to be due to a complete absence of all four
saposins (Sap-A,-B,-C, and-D) caused by a homoallelic mutation in the initiation codon of the common
saposin precursor prosaposin.4  Even though acid ceramidase activity was deficient and ceramide
accumulated in the tissues, the phenotype of this last patient resembled infantile Gaucher disease rather
than Farber disease. Three further cases of similar prosaposin deficiency have been described 
recently.5, 6
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Table  3 - Mutations in the ASAH1 gene reported in FD patients. 
DNA 
 Change 
Exon/intron Protein Change Subunit Age of 
Death 
(years) 
Farber 
Subtype 
References 
c.66G>C 1 Q22H 𝛼 NI NI  (Zhang et al., 2000) 
c.67G>C 1 H23D 𝛼 NI NI (Zhang et al., 2000)  
c.107A>G 2 Y36C 𝛼 2 1 (Bär et al., 2001)  
c.286_288del 4 V96del 𝛼 6.3 2 (Muramatsu et al., 2002)  
C.290T>A 4 V97E 𝛼 >10 2/3 (Muramatsu et al., 2002)  
c.413A>T 6 E138V 𝛼 30 3 (Li et al., 1999; Bär et al., 2001; 
Muramatsu et al., 2002)  
c.412G>T 6 G128_K152del 
E138X 
𝛼𝛽 >1.5 3 (Bär et al., 2001)  
Not found 6 G128 𝛼𝛽 30 3 (Bär et al., 2001)  
c.544C>G 8 L182V 𝛽 0.5 
brother:2 
1 (Devi et al., 2006)  
c.665C>A 9 T222K 𝛽 1.9 1 (Koch et al., 1996; Li et al., 1999)  
c.703G>C 9 G235R 𝛽 >10 2/3 (Muramatsu et al., 2002)  
c.760A>G 10 R254G 𝛽 NI NI (Li et al., 1999; Kostik et al., 
2013)  
 
c.833C>T 11 P278L 𝛽 >1.3 2/3 (Levade et al., 2009)  
c.958A>G 12 N320D 𝛽 2.5 6 (Zhang et al., 2000; Bär et al., 
2001)  
c.991G>A 12 D331N 𝛽 >1.5 3 (Bär et al., 2001)  
c.1085C>T 13 P362R 𝛽 1.5 1 (Li et al., 1999)  
IVS13+1G>T 13 N348_K366del 𝛽 3 5 (Bär et al., 2001)  
c.1187insT 14 X396L 𝛽 NI NI (Zhang et al., 2000)  
c.917 + 4A > 
G 
Intron 11 p.Tyr42_Leu127deli
nsArgfs 
 
𝛽 3days 4 (Alves et al., 2013) 
c.290T>G 4 p.V97G 
 
 ------- 1 (Chedrawi et al., 2012)  
c.502G >T 7 G168T 𝛽 38.5 
months 
 
1 (Cvitanovic-Sojat et al., 2011)  
c.1144 A > C 13 C p.K382Q) 
 
 -------- 2 (Jasmi, 2012)  
c.533 T > C 8 p.W185R 
 
 -------- 2 (Jasmi, 2012) 
  
 
 
 
 
As a consequence of these mutations, patients develop various symptoms, which 
may be more or less severe. The pathophysiological basis for the clinical heterogeneity of 
FD remains unknown. Presently, there is still some controversy about the correlation 
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between the clinical severity and either the residual ACDase enzymatic activity or the 
extent of Cer storage. Most of Farber patients tested so far had less than 6% of normal 
ACDase activity as measured in a variety of tissues (Jameson et al., 1987). Previous 
studies have shown that the level of stored Cer in the lysosomes is significantly correlated 
with the neurodegenerative course of FD and the age of death of the patient (Levade et 
al., 1995). However, another study reported no correlation between the levels of residual 
ACDase activity and the degree of Cer accumulation or symptom severity (Van Echten-
Deckert et al., 1997). 
 
 
 
4.3 Treatment 
Until now there is no effective treatment for Farber’s disease and most patients die 
at a very young age. The most frequent treatments consist on palliative treatment, 
administration of corticosteroids for the pain, tracheostomy to relieve respiratory 
difficulties, and surgery to remove the granulomas (Haraoka et al., 1997; Levade et al., 
2009). Current treatments result in improvement of symptoms but they do not improve the 
longevity of these patients (Yeager et al., 2000). Early diagnosis is therefore important 
and can be done using cultured amniocytes from the amniotic fluid to assay the ACDase 
enzymatic activity. This method can be very useful for parents who want making selective 
abortion of affected fetuses (Dulaney et al., 1976).  
 
Some treatments have focused on replacement of the missing enzyme responsible 
for the disease. Elizabeth Neufeld between 1960s and 1970s considered the possibility 
that allogeneic BMT might provide treatment and disease amelioration for LDSs (Malatack 
et al., 2003). These transplantations were performed in some Farber patients in whom an 
increase of ACDase enzymatic activity was observed. This treatment resulted in 
diminished joint discomfort, improved joint mobility and hoarseness. However, the 
prognosis was unfavorable and did not improve the longevity of these patients (Yeager et 
al., 2000; Zhang et al., 2000). There are also reports on improvement of the peripheral 
manifestations of infantile ACDase deficiency upon allogeneic BMT. However, this 
treatment did not result in the prevention of the progressive neurological deterioration, 
even when carried out in minimally symptomatic patients (Yeager et al., 2000). The 
economic incentive for the development of enzyme replacement therapy for FD is low, 
because there are few patients all over the world. However, the development of improved 
alternative treatment modalities remains important.  
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Objectives  
 
The aims of this thesis are: 
 
1) Qualitative assessment of primary and secondary buildup of lipids in Farber disease 
patients’ derived fibroblasts. 
 
2) Characterization of the C16-Cer/Chol microdomains in Farber disease and other LSDs 
patients’ derived fibroblasts. 
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Materials and Methods 
 
1. Materials 
 
1.1 Cell Lines 
All cell lines from human skin fibroblasts, 20015, 20016, 20017, 20018, 2314, 2315, 
5752, 18313 (see table 4) and 2316 (Farber carrier), were obtained from NIGMS Human 
Genetic Cell Repository. The patient’s cultured fibroblasts, Moh mock inf 5x, Farber 
transduced fibroblasts with ACDase cDNA, Moh corrected 5x and x10 retroviral correction 
(Accer 5x and 10x), (Medin et al., 1999) and Schr (prosaposin deficiency) (Sap) (Chatelut 
et al., 1997), were a kind gift from Professor Thierry Levade (Laboratoire de Biochimie, 
Maladies Métaboliques, Institut Louis Bugnard, Toulouse, France). Normal human skin 
fibroblasts (Wild Type 1 to 4) (WT) and fibroblasts from Niemann-Pick type B (NPB), 
Niemann-Pick type C1 (NP-C1), Gaucher type 2, Krabbe, Fabry disease, 
mucopolysaccharidoses (MLD), GM1-gangliosidosis (GM1), neuronal ceroid 
lipofuscinoses type 3 (CLN-3) and I-cell disease (ICD) were kindly provided by Doctor 
Lúcia Lacerda from the National Health Institute Dr. Ricardo Jorge Centro de Genética 
Médica Dr. Jacinto de Magalhães, Portugal. 
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Table 4 - NIGMS cell lines from Farber patients, specifying age of death and type of Farber disease, according to the 
classification of Moser 
Farber patients Age of death  Type  Rated  
20015 2 years  Type 1  Classical  
20016 2.5 years  Type 6  Combiation 
Sandhoff  
20017 3 years  Type 5  Neurologic 
Progression  
20018 22 months  Type 1  Classical  
2314 6 years  Type 2-3  Mild  
2315 30 years  Type 3  Mild  
5752 6 months  Type 4  Neonatal  
18313 11 months  Type 4  Neonatal  
 
1.2 Cell culture  
Cells were cultured in Dulbecco’s Modified Eagle medium (DMEM) with 10% fetal 
bovine serum (FBS), both from Gibco Invitrogen (Carlsbad, CA), and penicillin (100 U/ml), 
and streptomycin (100 µg/ml) (BD Biosciences, San Jose, CA).   
 
 
1.3  Antibodies 
Mouse monoclonal antibody anti-GM2 (IgM) was kindly provided by Doctor Tai 
(Department of Neurobiology, School of Life Sciences, Tottori University Faculty of 
Medicine, Yonago, Japan); anti-mouse (Fab')2 IgM µ-chain specific, conjugated with 
fluorescein was obtained from Sigma Aldrich (St Louis, Missouri, MO). The following 
antibodies were used: anti-voltage-dependent anion-selective channel protein 1 (VDAC1), 
anti-LAMP2a, anti-calnexin and anti-Rab7 (Abcam, Cambridge, UK); anti-Rab5 (Santa 
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Cruz Biotechnology Inc., Santa Cruz, CA, USA); anti-Golga5 (Sigma-Aldrich, St Louis, 
Missouri, MO); Cy2- and Cy3-labeled secondary antibodies (Jackson Immunoresearch, 
West Grove, PA, USA). An anti-mouse Fab fragment conjugated to 1.2 nm colloidal gold 
was from Nanoprobes (Yaphank, NY, USA). 
 
1.4  Lipids and Lipid Derivatives 
BODIPY-lactosylceramide (BODIPY-LacCer) was kindly provided by Dr. Robert 
Bittman (Department of Chemistry and Biochemistry, Queens College of The City 
University of New York), BODIPY-C5-Cer (N-(4,4-difluoro-5,7-dimethyl-4-bora-3a,4a-
diaza-s-indacene-3-pentanoyl) and BODIPY-C5-SM (N-[5-(5,7-dimethyl boron 
dipyrromethene difluoride)-1-pentanoyl]-D-erythro-sphingomyelin) were purchased from 
Molecular probes, Filipin complex was obtained from Sigma Aldrich (St Louis, Missouri, 
MO).  
 
1.5 Other Reagents  
Silica gel 60 thin-layer chromatography (TLC) 20x20 plates were from Merck 
(Darmstadt, Germany), bovine serum albumin (BSA) from Sigma Aldrich St Louis 
(Missouri, MO), protease inhibitor cocktail (Roche Diagnostics Ltd, Mannheim, Germany), 
glass coverslips (Fisher Scientific), elvanol mounting medium (Molecular Probes-
Invitrogen), formaldehyde solution from Sigma Aldrich St Louis (Missouri, MO), 
vectorShield was obtained from (Vector Laboratories), ethylenediamine tetraacetic acid 
(EDTA) phenol red solution from Gibco Invitrogen (Carlsbad, CA) and Lipoprotein-
deficient Serum (LPDS) from Sigma  (Missouri, MO). 2-hydroxypropyl-β-cyclodextrin (CD) 
was from Sigma-Aldrich (St Louis, Missouri, MO). Wheat germ agglutinin (WGA), Texas 
Red and 4'6-diamidino-2-phenylindole (DAPI) were from Molecular Probes (Eugene, OR, 
USA). All other reagents or solvents were of the highest grade. 
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2. Methods 
2.1.  Cell culture  
 
Fibroblasts were maintained in culture medium DMEM supplemented with 10% of 
FBS and antibiotics (10.000 U/ml streptomycin / penicillin and 1 mg/ml fungizone), at 37ºC 
in 5% CO2. A 20mmol/l Tris/0.25mol/l sucrose solution, pH 7.4, was used as washing 
solution. Cell passage was achieved by flowing trypsin/EDTA phenol red solution. 
 
 
2.2.   Lipid Extractions and High performance thin layer chromatography 
(HPTLC) Analysis 
Cell pellets were suspended in 1mL of methanol and sonicated twice (15 seconds 
each time) (W-375 Ultra-sonic model, Heat Ultrasonics-Systems, Inc.). Lipids were 
extracted and separated by reversed-phase chromatography according to the procedure 
previously described (Bligh and Dyer, 1959). Briefly, after lipid extraction, Bond Elut C18 
columns were placed in a Vac Elut column holder (Varian, USA). After column washing, 
the mixture was loaded and two fractions recovered as follows: the acid lipids were eluted 
with methanol/water (12:1 v/v) and neutral lipids with chloroform/methanol (1:2 v/v). The 
samples were dried under nitrogen stream and reconstituted with chloroform/methanol 
(1:2 v/v). Lipids were resolved by HPTLC (Linomat 5, Camag, Switzerland) developed in 
chloroform/methanol/ammonia (95:5:0.8 v/v/v) and visualized by incubating the plate at 
120ºC for 15 minutes after spraying with 1% solution of anisaldehyde in 80% of sulphuric 
acid after the plate was scanned.  
 
2.3.   Acid Ceramidase Assay 
Cell pellets were homogenate and added to a final volume of 200µL sucrose-EDTA 
buffer (0,25M sucrose, 0,001M EDTA) containing a protease inhibitor cocktail diluted 
1:200. Then citric acid was added in final concentration 0.1M and pH=4. The reaction 
initiated by addition of 4nmol of C12-NBD-Cer. The reaction proceeded for 3 hours at 37ºC 
in the dark and was terminated by addition of three volumes of chloroform:methanol (1:2 
by volume). Lipids were extracted according to Bligh and Dyer (Bligh and Dyer, 1959), 
and lipids from the lower phase were separated by TLC using chloroform: methanol: 
9.8mM CaCl2 (60:35:8 by volume) as the developing solvent. NBD-labeled SLs were 
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identified using authentic standards by the Fluor-S Max device and the bands were 
quantified by using Image Quant program (Amersham Biosciences). 
 
 
2.4. Cell Staining 
2.4.1. Incubation with lipids and lipid derivatives 
For BODIPY-C5-Cer cell incubation assay, the procedure was performed as 
described (Pagano et al., 1991). HSF cultures were plated in glass cover slips and 
incubated in LPDS media at 37ºC for 4 days, followed by 24h incubation in normal 
medium containing 100 µg/mL of LDL by incubating cultures with 2µM of lipid analogue for 
30 min at 37ºC. For BODIPY-LacCer assay, HSF cultures were plated in glass cover slips 
and incubated in LPDS media at 37ºC for 4 days, followed by 24h incubation in normal 
medium containing 100 µg/mL of LDL. The assay was then carried out as previously 
described (Martin and Pagano, 1994) using the 5µM of BODIPY-LacCer and an 
incubation period of 45 min. For BODIPY-C5-SM cell assay, the fibroblasts were plated in 
glass cover slips and incubated in LPDS media at 37ºC for 4 days, followed by 24h 
incubation in normal medium containing 100 µg/mL of LDL and then labeled with 2µM 
BODIPY-C5-SM complexed with BSA for 30 min at 37°C. The cells were imaged with a 
Nikon Eclipse E400 fluorescence microscope (λexc = 494 nm; λem = 518 nm) and charge-
coupled device Nikon Coolpix 950 camera. At least two independent experiments were 
performed. 
 
2.4.2. Immunofluorescence staining of GM2 
Cells were fixed with 3.7% formaldehyde in PBS pH 7.4 for 10 min at RT, rinsed 
twice with PBS, and permeabilized with 0.5% Triton X-100/PBS for 10 min at RT. After 
two washes, cells were blocked with PBS containing 1% BSA for 30 min. Cells were then 
incubated with monoclonal primary antibody anti-GM2 (IgM) (Kotani et al., 1992) 
previously diluted 1:50 in PBS, for 12–16 h at 4 °C. After washing three times with PBS 
cells were incubated for 1 h with secondary antibody (anti-mouse (Fab')2 IgM µ-chain 
specific, conjugated with fluorescein) previously diluted 1:75 (Sigma). After washing with 
PBS, coverslips were mounted with VectorShield (Vector Laboratories), imaged with a 
Nikon Eclipse E400 fluorescence microscope (λexc = 494 nm; λem = 518 nm) and charge-
coupled device Nikon Coolpix 950 camera. 
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2.4.3. Filipin staining 
 
Fibroblasts were stained with filipin and viewed by fluorescence microscopy 
according to Kruth et al. (Kruth et al., 1986). Briefly, cells were plated into chamber slides 
(Labteck slip, Nunc) in DMEM supplemented with 10% of FBS, at 37 °C with 5% of CO2 
for 24 h. The media was replaced by DMEM with 10% LPDS and cells cultured for 3 days 
before human LDL was added (100 µg/ml). The LDL fraction was prepared using blood 
from normal donors following the procedure described by Havel et al. (Havel et al., 1955). 
After a 24-h incubation with LDL in 10% LPDS media, cells were washed with PBS (three 
times for 5 min), fixed with formaldehyde 3.7% (v/v) for 10 min at room temperature. After 
washing twice with PBS, 0.1 mg/ml of fresh filipin was added to each slide and kept in the 
dark for 1 h. After washing in PBS, slides were mounted using VectaShield and visualized 
with a Nikon Eclipse E400 fluorescence microscope (λexc = 364 nm; λem = 475 nm).  
 
 
2.5. In vitro Acid Sphingomyelinase Enzymatic Assay 
 
The enzymatic activity of intracellular ASMase was determined essentially as 
previously described (Van Diggelen et al., 2005). Briefly, cell pellets were extracted in 
water by sonication (W-375 Ultra-sonic model, Heat Ultrasonics-Systems, Inc.). After 
centrifugation for 30 min at 15 000 g the supernatant, referred to as extract, was assayed, 
in duplicate, using Bicinchoninic acid (BCA) to determine protein concentration. In cell 
extracts, the enzymatic activity of ASMase was determined against the fluorogenic 
synthetic substrate 6-hexadecanoylamino-4-methylumbelliferylphosphorylcholine (HMU-
PC). The fluorescence was measured on a Hitachi F2000 spectrofluorometer. Standard 
solutions of 4-methylumbelliferone were used to calculate specific enzymatic activity. The 
activity of another lysosomal enzyme, β-galactoside, was also assessed as reference 
enzyme. 
 
2.6. Cell culture incubation with U18666A or desipramine 
 
Cells were plated in 3mL of culture medium on 60 mm dishes. The next day, the 
medium was removed and replaced with fresh medium supplemented with 10% LPDS. 
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After three days, the medium was renewed and supplemented with 4.5 µg/mL U18666A 
for 24 hours or 3µM desipramine for 1 hour. Cells were washed with PBS, fixed with 4% 
paraformaldehyde in PBS for 20 min and stained with 50 µg/mL of freshly prepared filipin 
solution in PBS for 1 hour at room temperature and stored in the dark. For in vitro acid 
sphingomyelinase enzymatic activity assay, cells were grown in 75-cm2 tissue culture 
flasks, harvested and immediately used or stored at -20°C. 
 
 
2.7. Studies with Anti C16-Cer/Chol antibody 
2.7.1. Production, screening and purification 
The Antibody anti C16- or C18-ceramide (anti-Cer/Chol) antibody was produced as 
previously described (Scheffer et al., 2006).  
The antibodies were initially purified from ascites fluid by affinity chromatography 
using an immunoPure IgM purification Kit (Thermo scientific-Pierce) according to 
manufacturer´s instructions. Only fractions with optical densities of >0.2 were pooled.  The 
purified antibody was extensively dialyzed against PBS and stored at 4ºC. Antibody 
concentrations were calculated using the antibody absorbance spectrum at 200-400nm. 
The antibody is stable up to 7 days after purification.  
 
 
2.7.2. Cell labeling 
Cells were cultured on 12-13 mm glass coverslips to a confluency of ~70%. Cells 
were fixed by incubating with 3% paraformaldehyde in PBS at room temperature for 45 
min, rinsed three times with PBS containing 0,003% BSA, first wash for 1 hour the 
following for 5 minutes each. After incubated for 1 hour with anti-C16-Cer/Chol antibody 
(10 µg/ml), cultures were rinsed three times with PBS containing 0,003% BSA 5 min each, 
and then incubated 45 min with the appropriate secondary antibody. Cells were mounted 
in Elvanol (12% elvanol, 3% glycerol, 60 mm Tris, pH 8.5, 1 mg/ml p-phenylenediamine) 
and observed 24 hours later. Acquisition was performed using a confocal FV1000 on 
Olympus IX81 microscope, using 1.35 NA UPLSAPO 60x oil objective (λexc = 490 nm; λem 
= 525 nm).  
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2.7.3. Immunofluorescent localization of C16-Cer/Chol domains  
Cells were cultured on 12-13 mm glass coverslips to a confluency of ~70%. Cells 
were fixed by incubating with 3% paraformaldehyde in PBS at room temperature for 50 
min, rinsed three times with PBS containing 0,003% BSA, first wash for 1 hour the 
following for 5 minutes each. After incubated for 1 hour with anti-C16/Chol antibody (10 
µg/ml), alone and with organelle markers. Antibodies to Rab 7 for endosomes, were used 
at a dilution of 1:50, Rab 5, for early endosomes, at 1:50, Golga5 for the Golgi, at 1:100, 
voltage-dependent anion-selective channel protein 1 (VDAC1) for mitochondria, at 1:180, 
Calnexin for ER, at 1:250 and Lamp 1 for lysosomes, at 1:180. Cultures were rinsed three 
times with PBS containing 0,003% BSA 5 min each, and then incubated 45 min with the 
appropriate secondary antibodies. The nucleus was stained using DAPI at a dilution 
5:5000 for 5 min. Cells were mounted in Elvanol and observed 24 hours later. Time-lapse 
acquisitions were performed using an Olympus confocal microscope. 
 
2.7.4. Incubation with 2-hydroxypropyl-β-cyclodextrin (CD) 
 
Cells were cultured on 12-13 mm glass coverslips to a confluency of ~70%. 
Fibroblasts were treated with 100 µM CD for 48h.  
 
 
 
 
2.8. Electron microscopy 
Fibroblasts of WT and of Farber (5752) cells grown on tissue culture plates were 
gently removed by washing. Fixation and labeling were performed as explained for 
fluorescence microscopy with the exception of the gold-conjugated (1.2 nm) secondary 
antibodies that were used. Enhancement of these particles, to a size of 10–30 nm, was 
performed using a Gold Enhancement kit (Nanoprobes, Yaphank, NY). The pellet was left 
overnight in 2% glutaraldehyde to allow further fixation. Prior to freezing, the pellets were 
washed by centrifugation (2900g, 4 min). Transmission electron microscopy (TEM) was 
performed using a chemically fixed cell pellet, which was labeled and enhanced using the 
same methods above mentioned. For immunolabeling the Tokuyasu preparation method 
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was used (Tokuyasu, 1973). Briefly, samples were infiltrated, cooled and embedded in 
gelatin and fixed with 2% glutaraldehyde on ice, cryo-protected in sucrose and vitrified by 
plunging in liquid N2. The frozen samples were cryo-sectioned using a Leica EM FC6 
cryomicrotome, and then transferred to bare 200-mesh nickel or format-coated TEM grids. 
Sucrose was removed; grids were stained with uranyl acetate, and embedded in methyl 
cellulose. Samples were viewed on a TEM, T12-Technai TEM microscope operating at 
120 kV. Images were recorded on an Eagle 2 K_ 2 K FEI camera (Eindhoven, 
Netherlands) 
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Results 
 
1. Rationale for the selection of FD and control cell lines  
Fibroblasts from FD are characterized by a primary accumulation of Cer. It is now 
known that in several LSDs secondary lipid storage also occurs, as in NP-C1, 
mucopolysaccharidoses, as well as some glycoproteinoses and ceroid lipofuscinoses, 
where GM2 and GM3 gangliosides levels are elevated as a consequence of the 
primary accumulation of Chol, glycosaminoglycans (GAG), oligosaccharides and ceroid 
lipofuscin-like autofluorescent lipopigments respectively. Secondary lipid accumulation 
in cells from FD patients has, so far, not been addressed. Therefore, one of the major 
aims of the present work is to investigate if there are secondary lipid accumulations in 
fibroblasts from FD patients and their implications in lipid trafficking. To this end, cells 
from the two most common forms of FD, subtypes 1 and 3, and the most severe form 
of FD described to date (caused by ASAH1 gene defects), subtype 4, were studied. 
The results indicated that, in addition to Cer, these cells also accumulated Chol (as will 
be described below in detail) and this prompted performing studies using an antibody 
that specifically recognizes Chol and C18/C16-Cer structured domains (Medin et al., 
1999; Goldschmidt-Arzi et al., 2011). The underlying aim of this part of the study was to 
identify if these lipids co-accumulated in the same cellular regions and thus potentiating 
the formation of these Cer/Chol-enriched structured domains. In these studies, in 
addition to the cells described above, fibroblasts from FD patients from all Farber 
types, 1 to 7 (see table 4) were also included in order to make the study more complete 
and representative, and to evaluate for a potential correlation between the severity of 
the mutation and the formation of Cer/Chol domains. To investigate if these domains 
were specific of FD or a common feature to other LSDs, these studies were also 
performed in a cell line representative of specific LSD. Accordingly, fibroblasts from 
NP-C1, NPB, Gaucher type 2, Krabbe disease, Fabry disease, metachromatic 
leukodystrophy, GM1 gangliosidosis, CLN-3 disease and I-Cell disease were used 
(Table 1). As described in the Introduction, each of these diseases accumulates a 
different substrate of an impaired enzyme: in NP-C1 the mutation causes a deficiency 
in Chol transporter, hence Chol accumulates. NPB disease is caused by the deficiency 
of ASMase, hence SM is accumulated; Gaucher type 2 disease is caused by 
glucocerebrosidase deficiency and hence glucosylceramide accumulation occurs; 
Krabbe disease is caused by a deficiency in galactocerebrosidase and as a result 
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galactosylceramide accumulates; Fabry disease is caused by the deficiency of alpha 
galactosidase A and accumulation of globotriaosylceramide (Gb3) ensues; 
metachromatic leukodystrophy (also called Arylsulfatase) is a disease caused by the 
deficiency of arylsulfatase  A and without this enzyme, sulfatides accumulate in many 
tissues; GM1 is caused by the deficiency of beta-galactosidase and consequent 
accumulation of GM1 ganglioside. CLN-3 disease is the juvenile form of Batten disease 
where there is an accumulation of lipofuscins. ICD is an inclusion cell disease, in which 
the phosphotransferase labeling a M6P on proteins designated to the lysosome is 
deficient; hence all proteins end up in inclusion bodies and later on out of the cell. In 
this study were used four different WT cell lines. 
 
 
2. Characterization of FD and control cell lines 
 
Prior to investigate downstream effects of lysosomal Cer storage in ACDase-
deficient cells, the level of total Cer was first assessed by lipid extraction and 
fractionation, and analysis by HTPLC (Figure 8). As could be anticipated, the level of 
total Cer was higher in FD cell lines compared to normal control cells. Overexpression 
of ACDase corrected this alteration, in agreement with previous studies (Medin et al., 
1999; Elojeimy et al., 2006). 
 
	  
Figure  8 - Qualitative assessment of intracellular Cer levels in cultured human skin fibroblasts (HSF). 
Cells were harvested, subjected to lipid extraction and fractionation and analyzed by HTPLC as described in Materials 
and Methods. Cer levels in normal control cells (Wt-1 and Wt-2) were compared to three different Farber cell lines (2315 
(Type 3); 20015 (Type 1); 20018 (Type 1)) and to FD cells overexpressing ACDase (retro viral correction (Accer 10x)). 
2315 20015 20018 Accer 10x Wt-1 Wt-2 Cer 
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The band doublet represents ceramides with fatty acids of distinct length (C16-C18 and C20-C24). Cer-20 was used as 
standard.  
To further characterize these cells, the activity of ACDase was quantified in FD, 
WT and FD carrier fibroblasts. To this end, C12-NBD-Cer was added as a substrate for 
the reaction. The lipids were separate by TLC using chloroform: methanol: 9.8 mM 
CaCl2 (60:35:8 by volume) and the bands corresponding to the fluorescent acyl chain 
degradation product were quantified using the Image Quant program (Amersham 
Biosciences) (Figure 9). The activity of ACDase was much lower in all Farber patients' 
fibroblasts, as can be seen by the very low substrate conversion compared to WT 
fibroblasts. The activity of the enzyme was also reduced in Farber carrier cells although 
to a much lower extent compared to WT (≈70%). Within the different FD subtypes there 
are some variations in enzyme activity, where the most severe cases, which belong to 
subtype 4 and 7, seem to have the lowest enzyme activity (≈4% and ≈7%, respectively, 
of substrate conversion). In all other FD cells the % of Cer conversion is slightly higher, 
between ≈ 8-15%, further confirming the correlation between the severity of the 
disease and the activity of ACDase, as previously shown (Medin et al., 1999). ACDase 
activity was also determined in an immortalized Farber patient cell line (Moh Mock inf 
5x) and its retroviral corrected version (Accer 5x and x10) (Figure 9). As previously 
shown (Medin et al., 1999) Moh Mock inf 5x was classified as subtype 4, and the 
activity of ACDase was reported to be very low in these cells (Medin et al., 1999). This 
is further confirmed in the present study, where the activity of the enzyme is 
comparable to other FD cells from subtype 4, i.e., ≈4% of Cer conversion. The activity 
of the enzyme was reestablished in the corrected cell line (Accer 5x and 10x) and a 
very high conversion was obtained, which corresponded to almost two times the WT 
percent conversion. 
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Figure  9 - In vitro activity assay of ACDase in HSF. 
Percent of ACDase substrate conversion quantified in WT, Farber carrier (2316), Farber fibroblasts (2314; 2315; 20015; 
20016; 20017; 20018; 18313; 5752; Sap and Moh Mock inf 5x) and retroviral corrected Farber fibroblasts (Accer 5x and 
x10) The lipids were extracted by the method described by Bligh and Dyer, 1959. C12-NBD-Cer was used as a 
substrate for the reaction and the acyl chain degradation product was measured. Bands were quantified by using Image 
Quant program (Amersham Biosciences). 
 
	  
	  
3. Secondary Lipid Accumulation in FD 
 
Previous studies showed that fluorescent lipid analogs can be useful tools to 
study lipid traffic between the Golgi apparatus and the PM of living cells (Pagano, 
2003). Furthermore, these studies highlight the potential of this assay to be used as an 
initial general screen for a broad group of lipid-storage diseases (Pagano et al., 2000; 
Pagano, 2003). 
The present study took advantage of these fluorescent lipid analogs to study lipid 
trafficking in FD cells. BODIPY-C5-Cer was used to study lipid traffic at the Golgi 
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complex and BODIPY-LacCer to study lipid transport along the endocytic pathway of 
HSF. 
Lipid analogs labeled with the BODIPY fluorophore were selected because 
BODIPY has unique spectral properties when compared to other fluorophores such as 
pyrene or NBD (Pagano et al., 1991; 2000; Marks et al., 2008). BODIPY is more 
photostable and the fluorescence emission is relatively insensitive to environmental 
factors like medium polarity, pH and oxygen (Pagano, 2003; Marks et al., 2008). In 
addition, it is possible to estimate the concentration of BODIPY-labeled lipid analogs, 
because the fluorescence properties of the probe change with its local concentration  
(Pagano et al., 1991; 2000). This is because two molecules of the dimethyl BODIPY 
fluorophore can form an excited state dimer, termed an excimer, that exhibits a second 
emission peak red-shifted from that arising from the excited monomer (Pagano et al., 
1991; 2000; Marks et al., 2008). Accordingly, when BODIPY fluorophore is present in 
membranes at relatively high concentrations, the typical green emission of the 
monomer is partially quenched and a second emission peak, derived from excimer 
emission, is observed at higher (red) wavelengths (620 nm). Due to these special 
properties, BODIPY can be used to monitor lipid accumulation in the lysosomes of SL 
storage diseases. In the present study, the intracellular lipid distribution in fibroblasts 
from patients with various SL-storage diseases such as Farber, NPC, and NPB was 
studied. To this end, fluorescence imaging of cells labeled with BODIPY-lipid analogs 
was performed using 450–490 nm for excitation, and the emission was collected in 
three different channels: green (520–560 nm), green+red (520 nm) and red (590 nm) 
(Puri et al., 1999; Marks et al., 2008).  
 
 
3.1.  Trafficking of endocytosed Cer 
 
The distribution of endocytosed Cer was assessed in different cell types such as: 
ACDase-deficient (2315 (Type 3); 20015 (Type 1); 20018 (Type 1); Moh Mock inf 5x 
(Type 4)), FD cells overexpressing ACDase (Accer 10x) and WT. The cells were 
treated with the analogue BODIPY-C5-Cer and analyzed by fluorescence microscopy 
(Figure 10). 
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Figure  10 - Endocytosis and intracellular distribution of BODIPY-C5-Cer in HSF.  
HSF were plated in glass cover slips and incubated in LPDS media at 37ºC for 4 days, followed by 24h incubation in 
normal medium containing 100µg/mL of LDL. Then the cells were incubated for 45 min with the lipid analog at 37°C in 
culture medium containing 2µM BODIPY-C5-Cer/BSA, washed, and further incubated for 1 h at 37°C in culture medium 
(Pagano et al., 1991; 2000a; Castro et al., 2009). The fluorescent lipid present at the PM was removed by back-
exchange with 5% BSA and analyzed by fluorescence microscopy. WT; FD cells (2315 (Type 3); 20015 (Type 1); 20018 
(Type 1); Moh Mock inf 5x) and cells overexpressing ACDase (Accer 10x) were treated with the analogue BODIPY-C5-
Cer and imaged with a Nikon Eclipse E400 fluorescence microscope (λexc. = 494 nm; λemi. = 518 nm) and charge-
coupled device Nikon Coolpix 950 camera. Representative images from n=30 cells, are shown. 
 
 
 
 
 
Imaging of the cells by fluorescence microscopy using the green+red channel, 
revealed a bright perinuclear and reticular pattern of fluorescence coincident to the 
Golgi complex. However, the fluorescence intensity was considerably higher in FD cells 
(20018; Moh Mock inf 5x) and a shift from green to red wavelengths, indicative of 
BODIPY excimer formation and thus, of a higher local concentration of probe, most 
probably in Golgi apparatus membranes, was noticed in FD fibroblasts (20018; Moh 
Mock inf 5x). These results suggest that BODIPY-C5-Cer and its metabolites (SM and 
glucosylceramide) can accumulate in the Golgi apparatus (Puri et al., 1999; Marks et 
al., 2008). Overexpression of ACDase reduced the Golgi Cer levels seen in the disease 
cell counterparts. Due to technical limitations it was impossible to make a quantitative 
comparison of the fluorescence intensities and show the different channel colours.    
 
WT 2315 20015 
20018 
Moh	  	  Mock	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3.2. Trafficking of endocytosed LacCer 
 
The distribution of the internalized fluorescent glycosphingolipid 
lactosylceramide-analog was assessed using BODIPY-LacCer. In this study, in addition 
to the cell lines described above, NPC fibroblasts, which accumulate cholesterol and 
BODIPY-LacCer (Puri et al., 1999; 2001), were used as a positive control. 
Internalization of BODIPY-LacCer results in a punctuate endosomal pattern of 
fluorescence and enhanced Golgi labeling of cells from Farber patients (20015 (Type 
1); 20018 (Type 1) and Moh Mock inf 5x (Type 4)) and NPC. In contrast, control cell 
line, corrected Farber Cell line Accer 10x and Farber cell line 2315 (Type 3) the 
fluorescent LacCer was uniquely targeted to the Golgi (Figure 11). Farber cell line 2315 
corresponds to a mild form of the disease and therefore, it was antecipated that 
alterations in endocytic trafficking subsequent of the disease were not as marked as 
observed for the other FD cells. These results are in agreement with previous reports 
for this cell line (Pagano et al., 2000).  
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Figure  11 - Endocytosis and intracellular distribution of BODIPY-LacCer. 
 Briefly HSF from normal cells (WT), Farber patients (2315; 20015; 20018; Moh Mock inf 5x) and NPC patients were 
plated in glass cover slips and incubated in LPDS media at 37ºC for 4 days, followed by a 24h incubation in normal 
medium containing 100µg/mL of LDL; labeled for 45 min at 37ºC with 5µM BODIPY-LacCer, washed and then chased 
for 1 h at 37°C. Fluorescent lipid present at the PM was removed by back-exchange with 5% BSA and imaged with a 
Nikon Eclipse E400 fluorescence microscope (λexc. = 494 nm; λemi. = 518 nm) and charge-coupled device Nikon 
Coolpix 950 camera. Representative images from n=30 cells are shown. 
 
 
As observed for cells labeled with the fluorescent BODIPY-C5-Cer, the 
fluorescence of BODIPY-LacCer displays a red-shift in its emission in fibroblasts from 
FD cell lines 20015, 20018 and Moh Mock inf 5x, as well as in the positive control NPC 
cells. These results suggest an increased probe concentration in Golgi apparatus. This 
was not observed for the other studied cells. 
BODIPY-LacCer is internalized from the PM to the Golgi complex in normal 
human skin fibroblasts, but is targeted predominantly to endosomes and lysosomes in 
fibroblasts from LSDs, suggesting a common mechanism of cellular dysfunction in 
these biochemically distinct disorders (Chen et al., 1997; Puri et al., 1999;2001; 
Pagano et al., 2000; Marks et al., 2008).  
For the same reason as mentioned above it was not possible to quantify the 
intensity of the probe and to present the different channels in colored images. 
WT NPC 
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3.3 Trafficking of endocytosed SM 
Previous studies showed the fluorescent lipid BODIPY-C5-SM is transported 
predominantly to the Golgi apparatus, while in the mutant NPB cells, which have a 
defect in the lysosomal degradation of SM, the fluorescent lipid is transported to the 
lysosomes and accumulates there (Koval and Pagano, 1990). After adding BODIPY-
C5-SM to these cells, the concentration of the lipid analog increases in the lysosomes 
and there is a shift in its fluorescence emission from green to red wavelengths (Pagano 
et al., 2000a; Marks et al., 2008). In order to evaluate for putative alterations in SM 
trafficking in FD, different cell lines FD 2315 (Type 3); 20015 (Type 1); 20018 (Type 1); 
Moh Mock inf 5x (Type 4) were labeled with BODIPY-C5-SM. These studies were also 
performed in cells overexpressing ACDase (Accer 10x), WT cells, and NPB and NPC 
cells were used as a positive control. Representative results of BODIPY-C5-SM 
distribution in these cells lines are shown in figure 12. 
 
 
 
Figure  12 - Endocytosis and intracellular distribution of BODIPY-C5-SM.  
Normal (WT), FD (2315; 20015; 20018; Moh Mock inf 5x), NPB, NPC and cells overexpressing AC (Accer 10x) HSF 
after incubation with BODIPY-C5-SM. Cells were plated in glass cover slips and incubated in LPDS media at 37ºC for 4 
days, followed by a 24h incubation in normal medium containing 100µg/mL of LDL. The cells were then labeled with 
2µM BODIPY-C5- SM complex with BSA for 30 min at 37°C, washed, and chased for 1 h at 37°C before back-exchange 
(Chen et al., 1997). Cells were imaged with a Nikon Eclipse E400 fluorescence microscope (λexc. = 494 nm; λemi. = 
518 nm) and charge-coupled device Nikon Coolpix 950 camera. Representative images from n=30 cells, are shown. 
WT NPB NPC 
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Some important differences in the labeling of the normal versus NPB fibroblasts 
are observed, which are in agreement with previous literature reports (Walkley and 
Vanier, 2009). First, in normal cells, most of the fluorescence is seen at the Golgi 
apparatus, (Pagano, 1990; Pagano et al., 1991; Rosenwald and Pagano, 1993), 
presented a pattern reticular and perinuclear, which is brightly labeled in the green and 
red microscope channels. In NPB cells, a bright punctate pattern of fluorescence is 
observed in both the ‘green’ and the ‘red’ microscope channels. This fluorescence 
pattern can also be observed in NPC fibroblasts. In Farber cells and cells 
overexpressing AC the fluorescence pattern was reticular and perinuclear, similar to 
observed in normal control cells. These results suggest that trafficking of endocytosed 
SM is largely unaffected in cells from FD patients. 
 
 
3.4. Cell ganglioside GM2 imbalance by staining with antibody anti-
GM2  
Secondary GSL accumulation has been documented in HSF (Walkley and 
Vanier, 2009) and mouse models in a wide range of LSDs, with or without primary 
defects in ganglioside degradation  (McGlynn et al., 2004). This accumulation is 
accompanied by sequestration of free Chol in a manner similar to that observed in 
primary gangliosidoses (Walkley and Vanier, 2009). To evaluate whether gangliosides 
accumulation also take place in FD, we investigated the accumulation of ganglioside 
GM2 in ACDase-deficient fibroblasts by immunofluorescence microscopy (Figure 13). 
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Figure 13 - Evaluation of secondary GSL accumulation in FD cells. 
Immunofluorescence analysis of ganglioside GM2 using an antibody anti-GM2 was performed in WT, FD cell lines 
(2315, 20015, 20018 and Moh Mock inf 5x) and the corrected version Accer 10x. GM2-gangliosidosis B1 variant was 
used as a positive control. The cells were imaged with a Nikon Eclipse E400 fluorescence microscope (λexc = 494 nm; 
λem = 518 nm) and charge-coupled device Nikon Coolpix 950 camera. Representative images of n=30 cells are shown. 
 
Comparison between the positive control cells GM2-gangliosidosis and Farber 
fibroblasts 2315 (Type 3), 20015 (Type 1), 20018 (Type 1) and Moh Mock inf 5x (Type 
4), suggest an accumulation of GM2, as shown by the strong labeling with the antibody 
anti-GM2 (see figure 13). This was not observed in WT and FD corrected cell line 
Accer 10x, indicating that there is no GM2 accumulation in normal fibroblasts. The 
punctate labeling pattern observed in FD fibroblasts suggests that the GSL is 
accumulated in the endosomal/lysosomal system when ACDase is deficient. 
Interestingly, FD cell line 2315, which corresponds to the less severe mutation, seems 
to display less GM2 accumulation suggesting a correlation between disease severity 
and secondary lipid accumulation. 
Secondary accumulation of gangliosides might be related to a Chol disturbed 
homeostasis. This would explain the intralysosomal trapping of GM2 in ACDase-
deficient fibroblasts. Therefore it is important to evaluate if Chol homeostasis is also 
altered in FD fibroblasts. 
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3.5. Cell Chol imbalance by Filipin staining 
 
An important issue with regard to several lysosomal storage diseases is actually 
the coordination of Chol metabolism with that of SM and of GSLs. Conversely, 
lysosomal accumulation of unesterified Chol secondarily affects SM metabolism 
(Walkley and Vanier, 2009). Not so far, it has further been shown that Chol plays a 
major part in regulating traffic of SLs along the endocytic pathway (Puri et al., 1999; 
2001). Indeed, lysosomal Chol overload correlates with abnormalities observed in NPC 
cells, but quite unexpectedly, these studies also showed that Chol homeostasis was 
perturbed in a number of sphingolipidoses, secondary to SL accumulation (Vanier et 
al., 1991; Walkley and Vanier, 2009).  
In several LSD high cellular Chol level was demonstrated to block Golgi targeting 
of BODIPY-LacCer while Chol depletion of LSD cells restored Golgi targeting of these 
lipids (Robinson and Karnovsky, 1980; Pagano et al., 2000a). The accumulation of 
endogenous lipids induces a redistribution of Chol which, in turn, leads to an alteration 
in the intracellular sorting of GSLs endocytosed via caveolae (for some SL such as SM 
a clathrin-dependent pathway can also be used to transport the lipid molecule to Golgi, 
however this pathway is not modulated by cellular Chol) (Puri et al., 2001).  
It is known that the incubation of fibroblasts derived from patients with NPC 
disease with LDL results in excessive intracellular accumulation of unesterified Chol 
(Kruth et al., 1986; Vanier et al., 1991; Abdul-Hammed et al., 2010).  
For the reasons described above, it seems that it is important to study cell Chol 
imbalance in cells from FD patients.  
Filipin is a polyene antibiotic and has been employed as a probe in biophysical 
studies of membrane structure, binding very specifically to certain sterols (usually Chol) 
in biological membranes (Robinson and Karnovsky, 1980; Vanier and Millat, 2003). For 
this reason, filipin complex is commonly used in the diagnosis of NPC patients (De 
Winter et al., 1992; Cenedella, 2009). To evaluate alterations in Chol traffic, the cells 
were thus stained with this polyene antibiotic. FD cells cultured in the presence of LDL 
showed filipin staining in perinuclear granules reflective of lysosomal Chol 
accumulation (Figure 14), implying that Farber cells are not capable of an efficient 
metabolism of free cholesterol. The positive control NPC classic cell lines showed a 
high lysosomal Chol accumulation (Figure 14) even without LDL overloading (not 
shown). Chol accumulation was not observed in cells overexpressing ACDase (Accer 
10x), even when these cells were overloaded with LDL, showing that restoring ACDase 
activity corrects Chol metabolism. These results are similar to the control WT cells. 
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These results suggest that a proper function of ACDase is necessary to maintain the 
Chol homeostasis (normal level of correctly distributed cell Chol) (Figure 14).   
 
 
 
 
Figure  14 - Cell Chol imbalance by Filipin staining.  
The cells were overloaded with LDL (100µg/ml) for 24-h as described in Materials and Methods and visualized with a 
Nikon Eclipse E400 fluorescence microscope (λexc. = 364 nm; λemi. = 475 nm). WT- normal HSF; NPC- positive 
control; 2315 (Type 3), 20015 (Type 1), 20018 (Type 1) and Moh Mock inf 5x (Type 4)- ACDase-deficient cells; Accer 
10x - cells overexpressing ACDase. T Representative images of n=30 cells are shown. 
 
 
4. Disruption of Chol and SL metabolism and trafficking in FD 
 
To further confirm the accumulation of Chol as a secondary lipid in FD, another 
strategy was employed. This strategy is based on literature evidence that shows an 
accumulation of Chol as a result of decreased activity of ASMase, as observed in NPB 
(Cenedella, 2009; Abdul-Hammed et al., 2010). As shown in Figure 15, filipin staining 
in NPB is increased compared to control cells and confirms an accumulation of Chol 
comparable to NPC cells.  
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We further investigated the effects of both Chol synthesis/transporter inhibitor 
and ASMase inhibitor drugs on ACDase and ASMase levels. To induce Chol 
accumulation U18666A was used, while ASMase activity was blocked by the use of 
desipramine. Our findings support the hypothesis that perturbation of Chol transport 
with U18666A influences ASMase activity in Farber, NPC and control cell lines. Our 
studies have also demonstrated that there may be a relationship between the decrease 
of ASMase activity and Chol accumulation. This was proven through the filipin staining 
of NPB cell lines, which carry a primary defect on ASMase, demonstrating a significant 
accumulation of free Chol (see figure 15). 
 
 
 
Figure  15 - Free Chol accumulation in NPC and NPB.  
The cells were overloaded with LDL (100µg/ml) for 24-h as described in Materials and Methods and visualized with a 
Nikon Eclipse E400 fluorescence microscope (λexc = 364 nm; λem = 475 nm). WT - normal HSF; NPB, NPC - positive 
control. Representative images of n=30 cells are shown. 
 
 
 
Furthermore, when treating normal control cell lines with an ASMase inhibitor 
(desipramine) and U18666A, we also observed Chol accumulation (see figure 16) 
together with the expected decrease of ASMase activity (see figure 17).  
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Figure  16 - Study of the effect of desipramine and U18666A in free Chol cell trafficking. 
Normal fibroblasts (WT) were grown in medium with or without Desipramine and U18666A for 24 h. Cells were imaged 
with a Nikon Eclipse E400 fluorescence microscope (λexc. = 494 nm; λemi. = 518 nm) and charge-coupled device 
Nikon Coolpix 950 camera. Representative images from n=30 cells, are shown.  
 
 
Figure  17 - Effects of desipramine and U18666A in aSMase activity of control cells. 
Normal fibroblasts were grown in medium with 4,5µg/ml of U18666A for 24 h, and 3,8µM of desipramine for 24h at 
37ºC. CT- Negative control; CT+desipramine – negative control was incubated with desipramine; CT+desipramine -; 
negative control after incubation with desipramine, and replaced for DMEM during 24h; CT+U18666A- negative control 
after incubation with U18666A.  
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Previous studies showed accumulated unesterified Chol in perinuclear 
cytoplasmic inclusions in fibroblasts from NPC patients (Vanier and Millat, 2003). This 
pattern can also be observed after LDL overloading causing excessive amounts of 
predominantly unesterified Chol accumulated (the same observed in Farber cells) (see 
figure 14).  
 
Initially, normal fibroblasts, Farber, and NPC fibroblasts were grown in medium 
with or without human LDL and U18666A for 24 h. In control cells unesterified Chol 
levels are low because the cell has the capacity to esterify of exogenous Chol. 
Treatment of normal cells and Farber fibroblasts with U18666A promotes an increase 
in Chol levels due to inhibition of Chol biosynthesis in agreement with previous reports 
(Cenedella, 2009). Removal of U18666A after 48 hours reverts the NPC phenotype 
induced by the inhibitor in these control cells, and decreased the accumulation of Chol 
(Figure 18). In the positive control cells, i.e., NPC cells, filipin staining revealed that 
Chol levels were already high in untreated cells, as expected due to the intrinsic 
accumulation of Chol in NPC cells (Figure 18). Treatment of NPC cells with U18666A 
enhanced the accumulation of Chol, in agreement with previous studies (Cenedella, 
2009). Removal of U18666A did not revert the phenotype and accumulation of Chol 
was still present in these positive control cells (Figure 18). In untreated FD cells, 
staining with filipin revealed increased levels of Chol compared to negative control 
cells, suggesting the accumulation of this lipid in FD cells. Treatment with U18666A 
further increased Chol levels and removal of the inhibitor did not revert the phenotype 
further supporting the intrinsic accumulation of Chol in FD cells. These results indicate 
that in addition to Cer accumulation, Chol is also accumulating in FD cells.  
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Figure  18 - Study of the effect of U18666A in free Chol cell trafficking.  
Normal fibroblasts (WT), Farber (20015 (Type1); 20018 (type 1), and NPC fibroblasts were grown in medium with (first 
column) or without (second and third columns) human LDL and U18666A for 24 h (second column). The third column 
represents the replacement for DMEM, and leaved for 48h. Cells were imaged with a Nikon Eclipse E400 fluorescence 
microscope (λexc. = 494 nm; λemi. = 518 nm) and charge-coupled device Nikon Coolpix 950 camera. Representative 
images from n=30 cells, are shown.  
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To induce NPB phenotype in FD and negative control cells, cells were treated 
with desipramine, which is an inhibitor of ASMase (Elojeimy et al., 2006). Treatment of 
negative control cells resulted in an accumulation of Chol (figure 19). This was reverted 
by removal of the inhibitor (figure 19 third column). In positive control cells, i.e., NPC 
cells, removal of the inhibitor did not revert the accumulation of Chol. Similar results 
were obtained in FD cells, as above mentioned untreated cells displayed increased 
filipin staining which was enhaced by the addition of ASMase inhibitor. Removal of the 
inhibitor did not revert Chol accumulation. These results further support the secondary 
accumulation of lipids in FD, particularly Chol.  
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Figure  19 - Study of the effect of desipramine in free Chol cell trafficking. 
 Normal fibroblasts (WT), Farber (20015 (Type 1); 20018 (Type 1), and NPC fibroblasts were grown in medium with (first 
column) or without (second and third columns) human LDL and desipramine for 24 h (second column). The third column 
represents the replacement for DMEM, and leaved for 48h. Cells were imaged with a Nikon Eclipse E400 fluorescence 
microscope (λexc. = 494 nm; λemi. = 518 nm) and charge-coupled device Nikon Coolpix 950 camera. Representative 
images from n=30 cells, are shown.  
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5. Identification of Cer/Chol “lipid domains” in FD fibroblasts  
 
The results presented above show that FD cells display a primary accumulation 
of Cer and a secondary accumulation of Chol and GM2. It was recently reported that 
Cer and Chol can coexist in the same domains (Castro et al., 2009) and form 
structured ordered domains in cell membranes (Goldschmidt-Arzi et al., 2011). This 
raised the hypothesis that these Cer/chol-enriched domains could exist in FD cells at 
the place where these lipids accumulate. To test this hypothesis, studies with an 
antibody able to recognize Cer/Chol domains were performed. This antibody 405F is 
enabled to recognize Chol/C16-Cer-mixed ordered domains (Scheffer et al., 2006). The 
Cer–Chol 405F specificity has been extensively studied (Scheffer et al., 2005; 2006; 
2007; Addadi et al., 2008; Goldschmidt-Arzi et al., 2011). Previous studies concluded 
that the binding specificity of this antibody depends on the acyl chain length of the Cer 
involved in the formation of these structured domains (Scheffer et al., 2005; 2006). It 
was shown that Cer–Chol 405F binds equally to monolayers composed of 60:40 mol % 
Chol/C16-Cer and 60:40mol% Chol/C18-Cer, but the binding affinity is decreased if 
ceramide has a longer acyl chain, e.g., in monolayers composed of 60:40 mol% 
cholesterol/C20-ceramide (Scheffer et al., 2006; 2007). In the present study it was 
further used as a control a monoclonal antibody-58B1, which binds to Chol crystal 
surfaces and to artificially Chol-enriched cell membranes, but not to individual Chol 
molecules (Scheffer et al., 2006; 2007; Goldschmidt-Arzi et al., 2011).  
 
To evaluate the formation of Cer/Chol structured domains all fibroblasts of WT 
and different subtypes of FD patients were grown on cover slips, then were fixed and 
labeled with anti C16 Cer/Chol antibody. The cells were viewed and Image capture by 
confocal microscopy and their intensity was evaluated by Olympus Fluoview FV1000 
software. The intensity was integrated and normalized over cell area. Some labeling 
could be detected in WT fibroblasts, with a similar distribution to that observed in a 
number of other cell types (Goldschmidt-Arzi et al. 2011), In contrast, substantially 
more intense labeling was observed in fibroblasts derived from a type 4 FD patient 
(Table 5), suggesting that C16-Cer/Chol domains accumulate in FD fibroblasts. Levels 
of C16-Cer/Chol domains were subsequently quantified in fibroblasts from FD patients 
of different severity. The most severe patients, namely the three type 4s and one type 
7, displayed the highest level of labeling (Table 5), which was ~3-5-fold higher than in 
control fibroblasts. Fibroblasts derived from patients who displayed a less severe 
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disease, or a patient who was a FD carrier, did not show elevated levels of C16-
Cer/Chol domains (Table 5). 
 
Table  5 - Intensity of Cer/Chol domains in fibroblasts of Farber patients. 
Fibroblasts of WT and Farber patients were fixed and labeled with anti C16 Cer/Chol antibody. Acquisition was 
performed using a confocal FV1000 on Olympus IX81 microscope, using 1.35 NA UPLSAPO 60x oil objective (λexc. = 
490 nm; λemi. = 525 nm). The intensity was integrated and normalized over cell area. The Farber fibroblasts are 
annotated by the age of death and subtype. Data shown are means ± SE (n=50 cells).  
 
 
 
We next determined whether levels of C16-Cer/Chol domains could be altered 
either by modifying Cer or Chol levels.  
For the former, we used human simian virus 40 (SV40) large T-transformed skin 
fibroblasts derived from a patient with type 4 Farber disease (Moh Mock inf 5x), which 
had been transduced with a recombinant retroviral vector containing the ASAH1 cDNA 
(Accer 10x) (Medin et al. 1999). As expected, the untreated cell line (Moh Mock inf 5x) 
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showed high levels of C16-Cer/Chol domains (Figure 20) whereas levels of the 
domains were reduced by ~7- fold in the ACDase-ovexpressing cells (Accer 10x) when 
compared to Moh Mock inf 5x (Table 5). 
	  
Figure  20 -Confocal immunofluorescence microscopy of HSF stained with anti-C16-Cer/Chol antibody. 
 Cells were incubated with anti-C16-Cer/Chol antibody as described in Materials and Methods and observation under 
the confocal fluorescence microscope FV1000 on Olympus IX81 microscope, using 1.35 NA UPLSAPO 60x oil objective 
(λexc. = 490 nm; λemi. = 525 nm). Images of fibroblasts labeled with C16 Cer/Chol antibody, negative control (WT), 
Farber type 4 (18313), Farber type 4 (Moh Mock inf 5x) and Retroviral corrected cells (Accer 5x). Cer/Chol domains 
decrease after ACDase retroviral correction. Magnification=×40. 
To further evaluate the correlation between lipid accumulation in FD and the 
amount of Cer/Chol domains, 5752 (Type 4) Farber fibroblasts were treated with CD in 
order to decrease the levels of Chol, as previously reported (Kilsdonk et al., 1995). This 
macromolecule is able to sequester Chol from the membranes (McCauliff et al., 2011). 
A significant decrease, ~6 fold, in the intensity of the C16-Cer/Chol domains was 
WT 18313 
Moh	  inf	  5x Accer	  5x 
10μm 
10μm 10μm 
10μm 
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observed n FD fibroblasts, with no effect on levels of the domains in WT fibroblasts 
(Figure 21). 
 
 
 
	  
Figure  21 - Effect of CD treatment on anti-C16-Cer/Chol labeling. 
Domain intensity was measured in WT-2 and 5752 (Type 4) untreated fibroblasts and after treatment with 100µM CD for 
48h. Values are means ± s.e.m., n = 2. 
 
6. Cellular localization of Cer/Chol cell domains in FD  
 
The intracellular location of the C16-Cer/Chol domains was further examined by 
co-localization with a number of organelle markers. As observed in earlier studies 
(Goldschmidt-Arzi et al. 2011), significant co-localization was observed in membranes 
of the endocytic pathway, including early and late endosomes and lysosomes but, 
unexpectedly, a significant increase in domain labeling was also observed in both the 
mitochondria and in the PM of type 4 Farber disease fibroblasts (Figure 22).  
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Figure  22 -Cellular localization of C16-Cer/Chol domains.  
The extent of co-localization between the anti-C16 Cer/Chol antibody and each of the markers was determined in WT-2 
and Type 4 fibroblasts. Values represent the extent of co-localization within one pair. Data are means ± s.e.m., n = 2. 
(*p < 0. 01, ** p < 0.0001). 
 
This localization was confirmed by immunogold labeling and TEM, in which 
significant labeling was detected in the mitochondria and in the PM (Figure 23). As for 
immunofluorescence microscopy, cells were fixed but not permeabilized, and labeled 
with the anti-C16-Cer/Chol antibody, followed by a secondary antibody conjugated to 
1.2 nm gold and by gold enhancement (Figure 23). Upon analyses in TEM the 
Cer/Chol domain labeling in the Farber type 4 samples in the mitochondria (Figure 23-
D) and PM 23-B) were viewed at higher quantity while in the WT fibroblasts sporadic 
gold particles were seen in both PM (Figure 23- A) and in the mitochondria 23-C).  
 
 
 
48  
 
domain intensities (data shown are means ± SE (n=50)), b- product formation of acid 
ceramidase and c- images of fibroblasts labeled with anti-C16-cer/chol antibody. (A) 
Retroviral corrected cells, (B) WT, (C) Farber type 4 (5752-6m) and (D) Farber type 4 
(Moh-3d)  
Next we examined the location of the cer/chol domains in type 4 Farber patients which 
presented an elevation in domain intensity. We used the fluorescent confocal microscope 
to co-localize the domains with organelle markers (Figure 5.4). The two organelles with a 
detectable change between the WT and the type 4 Farber patients were mitochondria and 
the plasma membrane. These two organelles do not belong directly to the endocytotic 
system. Labeling of plasma membrane with anti-C16-cer/ chol was not previously 
observed.  
  
Figure 5.4- Quantification of co-localization. The extent of co-localization between the 
anti-C16-Cer/Chol antibody and each of the markers was determined in Farber 
fibroblasts. The co-localization values represent the extent of co-localization within one 
pair, such that the numbers are not additive. Data shown are means ± SE,(*p < 0. 01,** 
p < 0.0001). 
** 
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Figure  23 - Visualization of Cer/Chol domains in the Plasma membrane (PM) and mitochondria by electron microscopy.  
Farber fibroblasts type 4 (5752-6m) and WT were labeled using the anti-C16 Cer/Chol antibody and a gold-conjugated 
secondary antibody. In the TEM images of WT/ Farber fibroblasts gold particles are seen as small black dots. WT PM 
(A) Farber PM (B) WT mitochondria (C) Farber mitochondria (D); (gold particles are indicated as magnified black dots); 
Scale 100 nm. 
 
	  
	  
7.  Cer/Chol domains are absent in other LSDs  
 
To understand if the increase in the occurrence of Cer/Chol domains is a 
phenomenon common among LSD's we grew fibroblasts of WT and different LSD 
patients with representative Farber fibroblasts on cover slips. The cover slips were 
fixed and labeled with anti C16 Cer/Chol antibody. The cells were imaged by confocal 
microscopy and their intensity was evaluated by Olympus Fluoview FV1000 software. 
The intensity was integrated and normalized over cell area (Figure 24). 
 
253 cholesterol or ceramide, suggests that ce amide sequesters
254 cholesterol in microdomains upon its accumulation in
255 Farber disease. This may be of relevance for understanding
256 the intracellular signaling pathways that are altered in
257 Farber disease, since many signaling pathways are modu-
258 lated by the membrane lipid composition (Foster et al.
259 2003). This is particularly true since significant levels of
260 C16-Cer/Chol domains were detected in the plasma
261 membrane, which is the main interface via which cells
262 sense their environment. Interestingly, cholesterol depletion
263 by CD dec eased levels f the domains. Whether choles-
264 terol depletion might be a therapeutic option in Farber
265 disease remains to be explored, it should be noted that we
266 have not detected elevated cholesterol in Farber disease, but
267 rather elevated sequestration of accumulated ceramide in
268 ceramide/cholesterol domains.
269 The accumulation of C16-Cer/Chol domains in mito-
270 chondria was unexpected, although a significant b dy of
271 data has been generated in the past few years demonstrating
272 that mitochondria are a key hub in ceramide biology
273 (Birbes et al. 2002). Indeed, ceramide levels in mitochon-
274 dria are elevated as a response to stress (Birbes et al. 2001;
275 Siskind et al. 2010), suggesting that Farber cells might be in
276 a constant state of cellular stress. The accumulation of C16-
277 Cer/Chol domains in the plasma membrane is easier to
278 explain, since the plasma membrane is both enriched in
279 cholesterol and part of the endomembrane system, and
280 perhaps once lysosomes become saturated with ceramide,
281 it could overflow into other interconnected compartments.
282Interes ngly, incre s levels of domains were only
283observed in the most severe forms of the disease, suggest-
284ing that a threshold level of ceramide accumulation is
285required before it can sequester cholesterol and thus be
286detected by the anti-C16-Cer/Chol antibody.
287Whether the anti-C16-Cer/Chol antibody might be used
288as a diagnostic tool for the most severe forms of Farber
289disease is open for discussion. Once a diagnosis of Farber
290disease has been made in the clinic (Dulaney et al. 1976)
291either by enzymatic or genetic analysis, the question of
292disease severity becomes relevant. The anti-C16-Cer/Chol
293antibody is able to distinguish the most severe forms of the
294disease in a relatively quick and inexpensive manner, but
295the few surviving patients with the severe forms of the
296disease are not conducive to widespread use of the antibody
297for diagnosis of severity. Moreover, the use of this antibody
298to demonstrate that ceramide is sequestered into domains
299containing chole terol suggests that previously unexpected
300cellular pathways might be involved in Farber disease
301pathology, which could lead to novel modes of therapeutic
302intervention.
303
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Fig. 5 Detection of C16-Cer/Chol domains by TEM. WT-2 and type 4
#1 fibroblasts were labeled using the anti-C16-Cer/Chol antibody and
a gold-conjugated secondary antibody, and examined by TEM. The
images are inverted (gold particles are indicated as magnified black
dots). The plasma membrane (PM) was identified via its invagina-
tions, and the mitochondria via their cisternae. Scale bar ¼ 100 nm
JIMD Reports
	   
A B 
C D 
 
 
 
	  
81	  
	  
	  
Figure  24 - Intensity of C16 Cer/Chol domains in fibroblasts from patients with different LSDs.  
Fibroblasts of WT and LSD patients were fixed and labeled with anti C16 Cer/Chol. The cells were visualized under the 
confocal fluorescence microscope FV1000 on Olympus IX81 microscope, using 1.35 NA UPLSAPO 60x oil objective 
(λexc. = 490 nm; λemi. = 525 nm). The intensity was integrated and normalized over cell area. Data shown are means ± 
SE (n=50).  
 
 
In all LSD fibroblasts used for this assay only one patient sample were used for 
each disease, therefore conclusions should be drawn carefully and relate to the 
specific subtypes of the disease presented only. The Cer/Chol domain elevation was 
not evident in any of the other LSD's examined here, when compared to Farber cell line 
from subtype 4 (5752) (Figure 24).  When evaluating the Cer/Chol domains labeling in 
the LSD fibroblasts we saw that only in Gaucher the elevation is slightly higher 
comparing to the WT and others LSDs. In Gaucher type 2 fibroblasts the cells showed 
a ~2 fold increase in Cer/chol domains intensity. However this result needs statistical 
confirmation, once in this study, it has been used only one Gaucher cell line. 
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Discussion 
 
Farber disease is an autosomal recessive storage disease caused by different 
mutations reducing or eliminating ACDase activity and leading to the accumulation of Cer 
in lysosome. The disease appears in heterogeneous population with no specific ethnicity 
or gender. As a result Cer accumulates in many different tissues presenting several 
different storage bodies some common to other LSD's and some unique Farber bodies 
(Schmoeckel and Hohlfed, 1979). The characterization of which lengths of Cer are 
accumulated among patients was never performed. The substrate specificity of the 
ACDase was studied, greater activity of ACDase in pH 4.5 was found when the Cer 
substrates containing shorter-chain fatty acids (C12-C18) or higher content of double 
bonds was seen (Momoi et al., 1982). Since these experiments were performed in vitro 
and involved the use of detergents a direct deduction to the biological system cannot be 
done. The main group of ceramides distributed in skin fibroblasts was identified as C22-
C24 being the major species (Goto-Inoue et al., 2012). Usually the diagnosis is made by 
measure the ACDase activity in skin fibroblasts. However the procedure is not so simple, 
once to obtain the protein amount take some time, and the diagnosis cannot be done so 
fast. For this reason becomes interesting and useful to do other studies, including 
secondary lipid accumulations, that help us to understand the mechanism of disease.   
 
1.  Secondary lipid accumulation in Farber Disease  
  
A relatively large subgroup of lysosomal storage diseases are caused by defects in 
enzymes and proteins required for lysosomal catabolism leading to accumulation of lipids 
in late endosomes or lysosomes (Simons and Gruenberg, 2000). An example already well 
studied, is NPD, which has more than one cause; NPA and NPB are characterized by SM 
accumulation, whereas Chol typically accumulates in the third form, NPC. The last one, 
that has accumulation of Chol in degradative compartments of the endocytic pathway is 
apparently due to a failure in the mechanism responsible for redistribution of Chol taken up 
by endocytosis of LDL, in contrast to other storage diseases caused by defective metabolic 
enzymes (Simons and Gruenberg, 2000). However previous studies have shown that, in 
addition to the major defect in Chol transport in NPC, SLs also accumulate in the 
multivesicular compartments of the endocytic pathway (Simons and Gruenberg, 2000).This 
is true not only for the NP diseases, since other SL storage diseases accumulate different 
SL classes in late endosomes/lysosomes. It turns out that cells from patients with 
sphingolipidoses also exhibit increased Chol levels in endocytic organelles (Simons and 
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Gruenberg, 2000). Indeed, it has been shown that endogenous lipids accumulate in the 
different LSD fibroblasts as a result of the primary defect in lipid catabolism, which then 
affect the intracellular distribution of Chol. This, in turn, leads to alterations in membrane 
composition that results in defective sorting and transport, which is typically monitored by 
following the trafficking of fluorescently-labeled SL analogs. Alterations in membrane 
trafficking and secondary lipid accumulation seem therefore widely common phenomena in 
many LSDs. However, this issue has so far not been addressed in FD, which prompted the 
investigation of putative secondary lipid accumulation subsequent of intralysosomal 
accumulation of Cer in fibroblasts from FD patients carrying different mutations. In 
addition, the studies performed in the framework of this thesis aimed to investigate if 
alterations in lipid trafficking and secondary lipid accumulation could be correlated with the 
severity of the disease. It has been described that secondary lipid accumulations in LDSs 
can belong to any of the major classes, Chol, phospholipids and GSLs, with different 
patterns in the different tissues often occurring in the same disease (Walkley and Vanier, 
2009). Accordingly, studies with fluorescent (BODIPY) SL analogues were performed in 
ACDase-deficient fibroblasts, to evaluate the biological impact of the intralysosomal 
accumulation of Cer on other cellular compartments and on secondary lipid accumulations, 
such as Chol and ganglioside GM2. 
Pagano and collaborators contributed greatly in this type of studies when used 
fluorescent derivative of lactosylceramide, a glycosphingolipid carrying the fluorescent 
BODIPY moiety in the fatty acid amide bonded to sphingosine. The authors have shown 
that the trafficking of this analog is disturbed in both Chol and SL storage disorders (Chen 
et al., 1999; Pagano et al., 2000). It is known that, in normal fibroblasts, after endocytosis 
at the PM, both SLs and Chol predominantly recycle to the PM (either directly or via the 
Golgi apparatus), possibly within SL/Chol enriched microdomains (Pagano et al., 2000). 
BODIPY-LacCer would partition into SL/Chol enriched microdomains at the PM or in 
endosomes, and the presence of high levels of SLs and Chol in LDSs would cause an 
increased fraction of SL/Chol enriched microdomain units to be shunted to the degradative 
pathway, possibly as a mechanism to regulate PM composition (Pagano et al., 2000). 
These phenomena could occur by exceeding the capacity of the recycling machinery by 
lipid environmental effects on proteins involved in sorting or by changes in ‘membrane 
architecture’. For instance, altered lipid composition could affect the curvature of nascent 
vesicles or tubules causing them to be recognized by different sorting proteins. 
Morphologic observation of lateral segregation of endosomal membranes into domains 
with higher and lower concentrations of BODIPY- LacCer would be consistent with this 
model (Pagano et al., 1991). The concentration-dependent spectral properties of the 
fluorophore BODIPY allow the identification of regions poor or enriched in the lipid analog, 
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as described in the results section, and thus, the identification of alterations in lipid 
trafficking. The model proposed by Pagano and collaborators supports the qualitative 
observations shown in figure 11, which demonstrate that BODIPY-LacCer accumulates in 
the lysosomes of the NPC, 20015, 20018 and Moh Mock inf 5x fibroblasts. These results 
are therefore suggestive of alterations in trafficking of SL and/or Chol, which might thus be 
associated to alterations in the composition of membrane microdomains and/or membrane 
properties. Such alterations were not observed in normal and 2315 fibroblasts. In these 
cells, BODIPY-LacCer labeling was mainly observed in the reticular and perinuclear region 
corresponding to the Golgi complex, in contrast to the punctate distribution observed in 
NPC, 20015, 20018 and Moh Mock inf 5x fibroblasts. 2315 corresponds to a mild form of 
FD, characterized by mental retardation and muscle weakness, the age at death was 30 
years old. At the molecular level, these cells have a significantly higher ACDase activity, 
when compared to the severe and very severe forms of FD patients. This certainly has a 
lower impact on the trafficking and accumulation of other lipid species compared to 
fibroblasts where the activity of ACDase is residual and Cer accumulation is elevated, such 
as observed in the classical (20018, 20015) and, neonatal (Moh Mock inf 5x) forms of the 
disease.  Further correlation between alterations in BODIPY-LacCer trafficking and the 
activity of ACDase could be established by studies in FD corrected cells, where the 
reestablishment of the activity of the enzyme corrected for the impaired LacCer trafficking. 
It can thus be concluded that deficiency in ACDase activity, as observed in FD, has 
implications not only at the level of intralysosomal Cer accumulation, but also on the 
trafficking and sorting of GSL, which might be derived from alterations in the composition 
of SL/chol microdomains, as previously suggested by Pagano and collaborators (Pagano 
et al., 2000; Pagano, 2003). Moreover, these alterations are dependent on the severity of 
the disease, being augmented in the more severe cases.   
 
Fibroblasts from NPC patients exhibit metabolic abnormalities in the cellular 
processing of LDL. All homeostatic responses associated with the cellular regulation of 
unesterified Chol levels were shown to be delayed in NPC fibroblasts.  For this reason 
LDL-Chol was abnormally sequestered in lysosomes of NPC fibroblasts, which resulted in 
impaired translocation of Chol to the PM (Distl et al., 2003).  
In this study were used two different drugs, U18666A and desipramine.  The first one 
is responsible to cause cellular phenotype similar to NPC cells by oxysterol binding protein 
(OSBP) dephosphorylation in the Golgi apparatus (Mohammadi et al., 2001). OSBP is a 
potential Chol regulator or sensor in the Golgi apparatus (Mohammadi et al., 2001).  
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The second, demonstrated in previous studies to be a specific ASMase inhibitor by 
induction of intracellular proteolytic degradation of mature ASMase but not other lysosomal 
enzymes (Elojeimy et al., 2006).  
ASMase degrades SM to Cer at the surface on the intraendosomal vesicles. 
Decrease of SM and increase of Cer enhances the availability of Chol on inner 
membranes for NPC2 which removes Chol from the inner endosomal vesicles and 
transfers it to the N-terminal domain of NPC1 in the limiting membrane of late endosomes 
(Abdul-Hammed et al., 2010). NPC1 mediates Chol exit through the glycocalix. Thus, SM 
accumulation due to lysosomal ASMase deficiency leads to defective Chol trafficking and 
efflux, which is believed, is due to sequestration of Chol by SM and possibly other 
mechanisms (Leventhal et al., 2001). 
The altered trafficking of fluorescent SL analogs in LSD fibroblasts is a multistep 
process and it has been further shown that Chol plays a major part in regulating traffic of 
SLs along the endocytic pathway (Pagano, 2003). Different studies, (Maxfield and Tabas, 
2005) suggested that high concentrations of Chol and SLs that accumulate in the 
endosomes of NPC cells could perturb endosomal sorting and reduce the amount of SL 
that can be transported to the Golgi. In this study we examined a fluorescent Cer analogue  
(BODIPY-C5-Cer) for studying lipid traffic at the Golgi apparatus in FD fibroblasts. Due to 
the concentration-dependent spectral properties of BODIPY-C5-Cer it was possible to 
visualize fine tubulovesicular processes extending from the Golgi apparatus (Pagano et al., 
1991). The spectral red-shift in the fluorescence emission of the BODIPY-lipid at the Golgi 
apparatus suggests that BODIPY-C5-Cer and its metabolites were present at this 
organelle in higher concentrations than in other regions of the cell (Pagano et al., 1991). It 
is possible that Cer turnover and/or its metabolites, SM and glucosylceramide, is delayed 
at the Golgi apparatus, further implicating alterations in the membrane composition and 
function including the distribution of GSLs at the trans-Golgi. Interestingly, it has been 
reported that SM levels are increased in FD fibroblasts, most likely due to delayed 
degradation (van Echten-Deckert et al., 1997). This might be a consequence of the 
sequestration of Cer and its metabolites at the Golgi apparatus, as observed in the present 
study. Accumulation of Cer in cellular membranes is expected to promote massive 
changes on membrane biophysical properties, including strong morphological alterations, 
as tubules, and formation of highly-ordered gel domains (Silva et al., 2007; 2009). These 
tubules together with the distinctive and highly ordered nature of Cer domains will certainly 
affect lipid and protein sorting and recycling, but might also modulate the activity of both 
integral and peripheral membrane proteins, as shown for instance, for SMase and PP2A. 
Alterations in membrane properties subsequent of Cer accumulation would therefore 
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globally contribute to the mistrafficking observed in FD fibroblasts and might even 
constitute one of mechanisms underlying the early stages of the disease. 
It has been shown that a secondary accumulation of GM2 ganglioside is a common 
feature associated with neuropathology in a number of LSDs, such as NPD and 
mucopolysaccharidoses, but also prosaposin deficiency, as well as some glycoproteinoses 
and ceroid lipofuscinoses (Walkley, 2004). Immunostaining studies applied to lysosomal 
diseases undergoing secondary lysosomal accumulation of GM2 have consistently shown 
that these gangliosides are sequestered in vesicles, appearing as punctate, granular 
structures within the cytoplasm of cells (Walkley and Vanier, 2009). This labeling has been 
documented in a wide variety of lysosomal diseases, such as NPA and NPC (both NPC1 
and NPC2 deficiencies), MPS diseases including type I, II, IIIA, VI, and VII, mucolipidosis 
type IV, several of the Batten disorders, including CLN2, CLN6 and CLN10 diseases, and 
α-mannosidosis (Walkley and Vanier, 2009). Lysosomal Chol overload correlates with 
abnormalities observed in NPC cells, but, some studies also showed that Chol 
homeostasis was perturbed in a number of sphingolipidoses, secondary to SL 
accumulation (Walkley and Vanier, 2009). 
We have shown that in fibroblasts from FD patients there is accumulation of both 
Chol and GM2 ganglioside. It can be suggested that, after the primary deficiency in the 
activity of lysosomal ACDase and accumulation of Cer in cells and tissue, the 
amount/composition of lipid rafts might be altered in the late endosomes. Previous studies 
showed that the degradation of SLs is normal when Chol is exiting normally from late 
endosomes (Walkley, 2004). In the same way, Chol removal from late endosomes would 
operate normally only when the SL content in the late endosomes is low (Walkley and 
Vanier, 2009). This phenomenon common to many LSDs, may be occurring in FD patients, 
as a consequence of the primary Cer accumulation and secondary lipid accumulations 
observed. Previous observations indicate that in LSDs involving lipids raft, the 
accumulation of one of the lipid raft components, such as Chol, SM or glucosylceramide, 
would slowly lead to trapping of other lipids raft components in late endosomes. The 
abnormal accumulation of any of these lipids would then jam both SL degradation and 
Chol trafficking (Simons and Gruenberg, 2000). Once Cer has been shown to interplay 
both with Chol or SM – key components of lipid rafts – and consequently changes the 
biophysical properties of raft domains (Silva et al., 2007; Castro et al., 2009; Silva et al., 
2009) it can be hypothesized that, the large amounts of Cer found in FD patients, might 
disturb SL/Chol metabolism and trafficking, resulting in their accumulation. The system late 
endosomes/lysosomes constitute the degradative compartments for SLs. The Cer effects 
on membrane properties are extremely dependent on membrane lipid composition, 
especially on Chol amounts. The proper function of this system depends on many factors, 
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such as the overall load of lipid rafts being endocytosed and recycled, and the balance 
between Chol and SLs (Castro et al., 2009). 
It should be noted that mistrafficking of GM2 as observed in FD fibroblasts, is 
certainly a consequence of the deficiency in ACDase activity and accumulation of Cer, 
since reestablishment of Cer levels in corrected FD cells (Accer 10x), and thus with normal 
ACDase activity, restores the normal distribution of GM2 within the cells.  
 
 
2.  Formation of Cer/chol domains 
The biological membranes are constituted by Chol-SLs interactions and they are 
important for the membrane organization, function, and structure developed (García-Sáez 
and Schwille, 2010). Since the publication by Singer and Nicolson in 1972 about fluid 
mosaic model many significant advance in the understanding of membrane organization 
are made. Many groups suggested introduction a new concept for PM model, once the PM 
does not exist only as a fluid, (liquid-crystalline phase), but in the PM and some organelles 
of the secretory and endocytic pathways in eukaryotic cells are rich in SLs, and as a 
consequence the lipid melting temperature increases, which can change the membrane 
properties and phase (Holthuis et al., 2001). SM is the most abundant SL present in lipid 
rafts (Xu et al., 2001), and together with Chol promote the membrane organization. The 
lipid raft model considers the lipids to be packed in dynamic liquid-ordered domains that 
are stabilized by specific proteins (Xu et al., 2001). These lipids rafts often referred to as 
lipid microdomains and result from the dynamic clustering between Chol and SLs (Simons 
and Ikonen, 1997) playing an important role in membrane trafficking and in signaling as 
well as pathological processes. Cer can be generated in stress conditions either from SM 
in rafts or from serine palmitoy-CoA by de novo pathway (catalysed by ceramide synthase) 
(Castro et al., 2009). Previous studies showed that Cer-induced alterations on membrane 
biophysical properties are dependent on the initial lipid composition, specifically from the 
Chol content. It is known that increasing Cer concentration leads not only to the formation 
of large and highly ordered Cer platforms, but also to morphological alterations in the 
vesicles, including aggregation, vesiculation, and tubular structure formation. Previous 
studies have shown that Cer-rich gel domains are formed at low but not at high Chol 
content (Castro et al., 2009). In fact in the presence of Chol, Cer would selectively displace 
Chol from rafts, competing for association with the other lipids, both in model and in cell 
membranes (Silva et al., 2007; Castro et al., 2009). In this study was used an antibody, 
anti-C16-Cer/Chol that was specifically selected to recognize organized arrays of 
cholesterol and C16-ceramide from a mixed phase with a well-defined structural 
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organization and does not recognize or bind to arrays composed of Cer or Chol by them 
selves (Scheffer et al., 2005). Previous studies have shown these domains were located in 
late endosomes (LEs) and in the trans-Golgi network. The ability of the anti-C16-Cer/Chol 
antibody to label LEs indicates that free Cer is present in LEs, and that at least some of 
this Cer is tightly associated with Chol (Goldschmidt-Arzi et al., 2011). This antibody is 
sensitive to the levels of Chol and Cer, as well as to the acyl chain length of the Cer 
forming these structured domains (Scheffer et al., 2006). Indeed, it has been shown that 
when cells were incubated with fumonisin B1, a ceramide synthase inhibitor that promotes 
a cellular reduction of ceramide, and labeled with antibody Cer–Chol 405F, the 
fluorescence signal was significantly reduced when compared to untreated cells 
(Goldschmidt-Arzi et al., 2011). In the contrary, cells overexpressing CerS5, CerS1 or 
CerS4, which lead to an increase in C16-, C18- and C20-ceramide, respectively, different 
levels of fluorescence were observed when the cells were labeled with the Cer–Chol 405F. 
The authors showed that CerS1 and CerS5 transfected cells had much higher levels of 
fluorescence than control cells, whereas the labeling in CerS4-transfected cells was similar 
to that of control cells (Goldschmidt-Arzi et al., 2011). This is due to the specificity of the 
antibody in recognizing structured domains of cholesterol with C16-ceramide/C18-
ceramide species (Goldschmidt-Arzi et al., 2011). Due to its characteristics, this antibody 
was employed as a tool to investigate if the primary accumulation of Cer and secondary 
accumulation of Chol altered the distribution pattern of these domains in FD cells and if 
these lipids accumulated together. In addition, the specificity of the antibody towards 
specific ceramides provides additional insights into the Cer species that accumulate in FD, 
an issue that has so far been overlooked. 
In the Farber fibroblasts we have documented the existence of the cer/chol domains 
in the two new cell locations, the PM and mitochondria; this finding directly indicates the 
presence of ceramides C16 and C18 with Chol in these locations. Since the antibody 
specifically recognizes structures composed of 40/60 mol% Cer/Chol, this is also an 
indication that the Chol concentration is higher than the Cer at least locally in the specific 
membrane and might hint that Chol accumulation plays a role in the patient's symptoms. 
Moreover if this is the case and chol is "trapped" in the cer/chol domains, a reduction of 
Chol will eliminate Cer/Chol domains increase, and might even improve the cell conditions 
(Ferreira et al., 2013). Indeed, treatment of the cells with CD, which sequesters Chol from 
the membrane, resulted in a decrease in the antibody-associated labeling of the cells, to 
levels comparable to normal cells.  
The Cer/Chol domain elevation was not evident in any of the other LSD's examined 
here, except in the case of Gaucher disease, there seems to be an increase, however 
these results need to be confirmed.  
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The existence of C16-C18 ceramides in skin fibroblasts is certain although not as 
high as longer ceramides, but these species certainly exists and since their metabolism is 
impaired the accumulated amount is significant for the Cer/Chol domain formation. In light 
of the antibodies binding site, which is around 20-25 molecules, many molecular 
recognitions events will happen upon Cer elevation. The domain formation could be a 
result of different reasons: the intuitive explanation is that domains of Cer and Chol are 
thermodynamic stable and therefore will form as a result of proximity in a membrane. 
Since Cer was not so abundant in these membranes in the WT cells the domains did not 
exist.   
This hypothesis, however, does not explain how the Cer arrived to these locations. 
Another observation that cannot be understood by the abundances of Cer is the lack of 
Cer/Chol domains increase in other Farber fibroblasts of different subtypes. We would 
expect to see gradual elevation depending on the severity in other Farber fibroblasts 
subtypes since Cer is clearly accumulating in them as well. Since this is not the case we 
propose another explanation with a biological nature. We suggest that the role Cer/Chol 
domains play in the signaling pathway upon stress is the main reason for the appearance 
of Cer/Chol domains in the mitochondria and the PM, a possibility worth further 
consideration in this context. The mitochondrial Cer pool was the focus of various works, 
which claimed that a Cer pool becomes apparent only when the mitochondria are activated 
and a stress pathway is initiated (Siskind et al., 2010).  
One paper shows Cer generation is independent of the known downstream actions 
of BAK (BcL2 homologous antagonist/killer) the protein identified as an initiator of 
apoptosis (via mitochondrial outer membrane permeabilization or caspase protein 
apoptosis marker activation), suggesting a role for BAK in apoptosis related to Cer with 
C16 or C18 acyl chains (Siskind and Colombini, 2000; Siskind et al., 2008; 2010).  
Another group of papers introduces the idea that C16-Cer, but not dihydroceramide, 
forms large channels in PM; this action did not trigger cytochrome C secretion or release, 
but simply raised the permeability of the mitochondrial outer membrane, via the Cer 
channel formation (Siskind and Colombini, 2000). 
Several inducers of cellular stress leading to apoptosis have been shown to cause a 
net increase in cellular Cer levels. This list of inducers causing Cer accumulation suggests 
that Cer is a crucial component of intracellular stress response pathways (Hannun, 1996). 
All these accumulating data, converge to the conclusion that Cer is involved in promoting 
cell stress. This reinforces our belief in the involvement of Cer/Chol domains as an optional 
biophysical mechanism to change membrane properties/ rigidity in stress cell conditions. 
Although no definite proof of the direct involvement of Cer/Chol domains in cell stress was 
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shown, we believe that the existence of the domains in mitochondrial membrane is by itself 
an important finding.     
We also found these new Cer/Chol domains in the PM (Ferreira et al., 2013). The 
domains in the PM were mostly seen in a proximity to a fusing vesicle and can be thus 
explained as an exocytosis mechanism in which some surplus lipids are taken out of the 
cell. This idea is reinforced by the connection found between Cer and exosomes. It was 
found that cargo taken into endocytotic organelles is segregated into distinct subdomains 
and the transfer of exosome-associated domains into the lumen of the endosome does not 
depend on the function of the ESCRT (endosomal sorting complex required for transport) 
machinery, but requires Cer (Trajkovic et al., 2008). In addition budding of blebs and 
shedding of vesicles is directly related to the formation of apoptotic bodies, the 
involvement of Cer as an inducer of this apoptotic process was established in the 
sphingomyelinase apoptotic pathway (Tepper et al., 2000). 
These concepts involving both mitochondria and PM with connection to Cer, clarify 
that Cer has a big role as structural, biophysical modifier of membrane processes and that 
the Cer/Chol domains might be an interesting way to control its involvement in Farber 
pathology.  
The mechanism of the Farber pathology and many other LSD's is not clear yet, and 
the involvement of a genetic background complicates the disease classification. The 
classification into different subtype emphasizes the different manifestations of the disease 
symptoms and probably the severance of the disease progression. The mutation type 
cannot be related to the different subtypes since a report of a family with 3 affected 
children each with a different Farber subtype were presented (Amirhakimi et al., 1976). 
Considering that the assay confirming Farber diagnosis are not straightforward when 
percent conversion is very low (under ~4%) and our assay detecting Cer/Chol domains 
clearly showed distinction only in subtypes 4 and 7 the very severe form of the disease, we 
conclude that our antibody labeling assay can be potentially used as a diagnostic tool for 
these severe cases. Our experimental procedure is simple fast and relatively low in costs. 
Using both fluorescence and electron microscopy we were able to detect a big 
elevation in Cer/Chol domains in fibroblast of the two most severe Farber subtypes, type 4 
and 7. These two subtypes are the earliest in the onset, both neonatal (Scriver, 1995) and 
in disease progression /death, and both yield the lowest values in the percent conversion 
in the ACDase assay. These cells could not overcome the enormous loads of Cer entering 
their endocytic pathway: this probably contributed to the extreme elevation in the intensity 
of the Cer/Chol domains. 
The existence of the Cer/Chol domains in the two particular subtypes might have a 
connection to the very different symptoms these patients present relative to the more 
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classical symptoms present in all other subtypes. Since the literature dealing with Farber 
disease and even more with the subtypes 4 and 7 is very limited we cannot attribute the 
Cer/Chol domain elevation to a specific pathway but we believe this finding will provide a 
new relevant direction to explore the disease mechanism and even the use of existing 
techniques used for cholesterol extraction as possible treatment for Farber patient. 
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Conclusion  
 
LDSs are complex diseases caused by a wide range of gene leading to protein 
defects and characterized by intracellular sequestration of multiple substrates, including 
GSLs, phospholipids and Chol. The storage-accumulated material can be diverse, and 
sometimes with no direct relation to the primary metabolic defect and are therefore 
considered as secondary, however, with a key role in the disease pathogenesis. In normal 
conditions, membrane components that are delivered to late endosomes and lysosomes 
are subject to hydrolysis by the hydrolytic enzymes in these organelles. This catabolic 
process is important for the normal turnover of lipid components, and a lack of activity 
from one of these hydrolases leads to an accumulation of the undegraded substrate for 
the missing hydrolase. In most of LDSs, the lipids accumulation can be seen in many 
tissues, however it can be observed in cultured fibroblast lines from the affected 
individuals. Usually, the brain is the most affected tissue, leading eventually to neuronal 
death and neurological complications that are often severe and frequently fatal. For 
example cholesterol accumulation occurs along with GSLs in many lysosomal diseases 
and evidence suggests that it may interfere with normal endosomal/lysosomal processing 
as well as lead to cholesterol deficits elsewhere in neurons, with consequences for 
neuronal function. Thus it becomes important to understand the cellular and subcellular 
locations, and the reasons for sequestration of the many secondary storage compounds in 
order to characterizing lysosomal disease for the full elucidation of the cell biology of 
these conditions. In the present study, we showed: 
1) Perturbations in GM2- Ganglioside and cholesterol homeostasis in FD fibroblasts 
secondary to SL accumulation. 
2) Lipid trafficking alterations by using a fluorescent Cer analogue (BODIPY-C5-Cer)  
3) Lysosomal buildup of LacCer by using BODIPY-LacCer, a fluorescent analogue.  
4) Elevated levels of cholesterol: C16-ceramide domains in fibroblasts from type 4 
and 7 FD patients, the most severe forms.  
 
We speculate that endosomal traffic jams caused by raft alterations in the 
degradative compartments might contribute to the clinical features associated with each 
lysosomal storage disorder. Altered trafficking and mistargeting of proteins can also 
contribute to the complex spectrum of these pathologies. 
At the cellular level, further studies to define the intracellular compartment(s) and the 
mechanisms by which altered SL sorting occurs in FD cells vs normal cells are required. 
Mechanisms for the redistribution of intracellular cholesterol in FD cells need to be 
evaluated. Further experiments devised to rigorously test microdomains and intralumenal 
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membrane-based sorting models for SL targeting should be performed. It will also be 
important to learn whether the current observations with fluorescent SL analogs extend to 
endogenous lipids, as suggested by preliminary studies. More work will be necessary to 
establish how cholesterol and sphingolipids are distributed in cells and how the regulation 
of their location affects cellular function. In addition to profiling the lipids which accumulate 
in FD cells, further studies on the linkage between SL accumulation and cholesterol 
redistribution should be performed by increasing the levels of natural SLs in normal 
fibroblasts and learning whether intracellular cholesterol redistributes in response to 
elevated SLs. 
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